US20090209514A1 - Tetrahydro-Naphthalene Derivatives as Vanilloid Receptor Antagonists - Google Patents
Tetrahydro-Naphthalene Derivatives as Vanilloid Receptor Antagonists Download PDFInfo
- Publication number
- US20090209514A1 US20090209514A1 US12/432,600 US43260009A US2009209514A1 US 20090209514 A1 US20090209514 A1 US 20090209514A1 US 43260009 A US43260009 A US 43260009A US 2009209514 A1 US2009209514 A1 US 2009209514A1
- Authority
- US
- United States
- Prior art keywords
- hydroxy
- tetrahydronaphthalen
- trifluoromethyl
- urea
- benzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *C.CC.Cn1c(COc2cccc(CC3SC(=O)NC3=O)c2)nc2ccc(Oc3ccc4cccc(NC(=O)Nc5ccccc5)c4c3)cc21 Chemical compound *C.CC.Cn1c(COc2cccc(CC3SC(=O)NC3=O)c2)nc2ccc(Oc3ccc4cccc(NC(=O)Nc5ccccc5)c4c3)cc21 0.000 description 16
- IEXBPOHVFRXFAC-MRXNPFEDSA-N CN(CCO)C1=CC(CNC(=O)NC2=CC=CC3=C2C[C@H](O)CC3)=CC=C1C(F)(F)F Chemical compound CN(CCO)C1=CC(CNC(=O)NC2=CC=CC3=C2C[C@H](O)CC3)=CC=C1C(F)(F)F IEXBPOHVFRXFAC-MRXNPFEDSA-N 0.000 description 2
- VJRPWJBHQJDMNW-UHFFFAOYSA-N O=C(NCC1=CC(C(F)(F)F)=C(N2CCCCCC2)C=C1)NC1=CC=CC2=C1CC(O)CC2 Chemical compound O=C(NCC1=CC(C(F)(F)F)=C(N2CCCCCC2)C=C1)NC1=CC=CC2=C1CC(O)CC2 VJRPWJBHQJDMNW-UHFFFAOYSA-N 0.000 description 2
- YLIZAPUBDWCSLQ-QGZVFWFLSA-N O=C(NCC1=CC=C(C(F)(F)F)C(N2CCCC2)=C1)NC1=CC=CC2=C1C[C@H](O)CC2 Chemical compound O=C(NCC1=CC=C(C(F)(F)F)C(N2CCCC2)=C1)NC1=CC=CC2=C1C[C@H](O)CC2 YLIZAPUBDWCSLQ-QGZVFWFLSA-N 0.000 description 2
- VOQCGSCAFJDFIJ-UHFFFAOYSA-N C1CCNCC1.NCC1=CC=C(C(F)(F)F)C(N2CCCCC2)=C1.[C-]#[N+]C1=CC=C(C(F)(F)F)C(F)=C1.[C-]#[N+]C1=CC=C(C(F)(F)F)C(N2CCCCC2)=C1 Chemical compound C1CCNCC1.NCC1=CC=C(C(F)(F)F)C(N2CCCCC2)=C1.[C-]#[N+]C1=CC=C(C(F)(F)F)C(F)=C1.[C-]#[N+]C1=CC=C(C(F)(F)F)C(N2CCCCC2)=C1 VOQCGSCAFJDFIJ-UHFFFAOYSA-N 0.000 description 1
- WNMGGECELGJRHG-UHFFFAOYSA-N C=C(NC)N[Ar]C.[Ar] Chemical compound C=C(NC)N[Ar]C.[Ar] WNMGGECELGJRHG-UHFFFAOYSA-N 0.000 description 1
- DPTGTHGBALOPEF-UHFFFAOYSA-N CC(C)(C)OC(=O)NC1=CC=CC2=CC=C(O)C=C21.CCOC1=CC=C2C=CC=C(N)C2=C1.CCOC1=CC=C2C=CC=C(NC(=O)OC(C)(C)C)C2=C1.CCOC1=CCC2=C(C1)C(N)=CC=C2.NC1=CC=CC2=CC=C(O)C=C12 Chemical compound CC(C)(C)OC(=O)NC1=CC=CC2=CC=C(O)C=C21.CCOC1=CC=C2C=CC=C(N)C2=C1.CCOC1=CC=C2C=CC=C(NC(=O)OC(C)(C)C)C2=C1.CCOC1=CCC2=C(C1)C(N)=CC=C2.NC1=CC=CC2=CC=C(O)C=C12 DPTGTHGBALOPEF-UHFFFAOYSA-N 0.000 description 1
- RSCGCRIOJMRLHR-UHFFFAOYSA-N CC(C)OC1=C(N2CCCC2)C=C(CNC(=O)NC2=CC=CC3=C2CC(O)CC3)C=C1 Chemical compound CC(C)OC1=C(N2CCCC2)C=C(CNC(=O)NC2=CC=CC3=C2CC(O)CC3)C=C1 RSCGCRIOJMRLHR-UHFFFAOYSA-N 0.000 description 1
- LFNHSEYNHJLEFU-UHFFFAOYSA-N CC(C)OC1=C(N2CCCC2=O)C=C(CNC(=O)NC2=CC=CC3=C2CC(O)CC3)C=C1 Chemical compound CC(C)OC1=C(N2CCCC2=O)C=C(CNC(=O)NC2=CC=CC3=C2CC(O)CC3)C=C1 LFNHSEYNHJLEFU-UHFFFAOYSA-N 0.000 description 1
- ZQULUVUKHAGFFB-UHFFFAOYSA-N CCOC(=O)C1CCN(C2=C(C(F)(F)F)C=CC(CNC(=O)NC3=CC=CC4=C3CC(O)CC4)=C2)CC1 Chemical compound CCOC(=O)C1CCN(C2=C(C(F)(F)F)C=CC(CNC(=O)NC3=CC=CC4=C3CC(O)CC4)=C2)CC1 ZQULUVUKHAGFFB-UHFFFAOYSA-N 0.000 description 1
- WOUBSSASOMKFBJ-UHFFFAOYSA-N CCOC1=CCC2=C(C1)C(N)=CC=C2.NC1=CC=CC2=C1CC(=O)CC2.NC1=CC=CC2=C1CC(O)CC2 Chemical compound CCOC1=CCC2=C(C1)C(N)=CC=C2.NC1=CC=CC2=C1CC(=O)CC2.NC1=CC=CC2=C1CC(O)CC2 WOUBSSASOMKFBJ-UHFFFAOYSA-N 0.000 description 1
- MIFVYWYZEQBSDJ-UHFFFAOYSA-N CN(C)CCNC1=C(C(F)(F)F)C=CC(CNC(=O)NC2=CC=CC3=C2CC(O)CC3)=C1 Chemical compound CN(C)CCNC1=C(C(F)(F)F)C=CC(CNC(=O)NC2=CC=CC3=C2CC(O)CC3)=C1 MIFVYWYZEQBSDJ-UHFFFAOYSA-N 0.000 description 1
- BVUBCLMSKYKKAF-UHFFFAOYSA-N C[Rb].[H]N(CC(CO[RaH])CC1=CC=CC=C1)C(=C)CC1=CC=C(C)C(OC)=C1 Chemical compound C[Rb].[H]N(CC(CO[RaH])CC1=CC=CC=C1)C(=C)CC1=CC=C(C)C(OC)=C1 BVUBCLMSKYKKAF-UHFFFAOYSA-N 0.000 description 1
- UYXDAHFISRYAHV-UHFFFAOYSA-N NC(=O)C1CCN(C2=CC(CNC(=O)NC3=CC=CC4=C3CC(O)CC4)=CC=C2C(F)(F)F)CC1 Chemical compound NC(=O)C1CCN(C2=CC(CNC(=O)NC3=CC=CC4=C3CC(O)CC4)=CC=C2C(F)(F)F)CC1 UYXDAHFISRYAHV-UHFFFAOYSA-N 0.000 description 1
- DDRQYVVBFIIIHZ-UHFFFAOYSA-N NC1=CC=CC2=C1CC(=O)CC2.NC1=CC=CC2=C1CC(O)CC2 Chemical compound NC1=CC=CC2=C1CC(=O)CC2.NC1=CC=CC2=C1CC(O)CC2 DDRQYVVBFIIIHZ-UHFFFAOYSA-N 0.000 description 1
- BSBQQDTURCAWDO-UHFFFAOYSA-N NC1=CC=CC2=C1CC(O)CC2.O=C(Cl)OC1=CC=CC=C1.O=C(NC1=CC=CC2=C1CC(O)CC2)OC1=CC=CC=C1 Chemical compound NC1=CC=CC2=C1CC(O)CC2.O=C(Cl)OC1=CC=CC=C1.O=C(NC1=CC=CC2=C1CC(O)CC2)OC1=CC=CC=C1 BSBQQDTURCAWDO-UHFFFAOYSA-N 0.000 description 1
- FXJJKEVGTHVANU-UHFFFAOYSA-N NCC1=CC=C(C(F)(F)F)C(N2CCCCC2)=C1.O=C(NC1=CC=CC2=C1CC(O)CC2)OC1=CC=CC=C1.O=C(NCC1=CC(N2CCCCC2)=C(C(F)(F)F)C=C1)NC1=CC=CC2=C1CC(O)CC2 Chemical compound NCC1=CC=C(C(F)(F)F)C(N2CCCCC2)=C1.O=C(NC1=CC=CC2=C1CC(O)CC2)OC1=CC=CC=C1.O=C(NCC1=CC(N2CCCCC2)=C(C(F)(F)F)C=C1)NC1=CC=CC2=C1CC(O)CC2 FXJJKEVGTHVANU-UHFFFAOYSA-N 0.000 description 1
- GLZIYBDJZFAAQH-UHFFFAOYSA-N O=C(NC1=CC=C(N2CCCCC2)C=C1)NC1=CC=CC2=C1CC(O)CC2 Chemical compound O=C(NC1=CC=C(N2CCCCC2)C=C1)NC1=CC=CC2=C1CC(O)CC2 GLZIYBDJZFAAQH-UHFFFAOYSA-N 0.000 description 1
- GQZDOZZIEZFMDX-UHFFFAOYSA-N O=C(NC1=CC=C(N2CCOCC2)C(Cl)=C1)NC1=CC=CC2=C1CC(O)CC2 Chemical compound O=C(NC1=CC=C(N2CCOCC2)C(Cl)=C1)NC1=CC=CC2=C1CC(O)CC2 GQZDOZZIEZFMDX-UHFFFAOYSA-N 0.000 description 1
- VROLIWZJWFXRDY-UHFFFAOYSA-N O=C(NC1=CC=C(N2CCOCC2)C=C1)NC1=CC=CC2=C1CC(O)CC2 Chemical compound O=C(NC1=CC=C(N2CCOCC2)C=C1)NC1=CC=CC2=C1CC(O)CC2 VROLIWZJWFXRDY-UHFFFAOYSA-N 0.000 description 1
- IKPRVTAASFTTOZ-UHFFFAOYSA-N O=C(NCC1=CC(N2CCC(C(=O)O)CC2)=C(C(F)(F)F)C=C1)NC1=CC=CC2=C1CC(O)CC2 Chemical compound O=C(NCC1=CC(N2CCC(C(=O)O)CC2)=C(C(F)(F)F)C=C1)NC1=CC=CC2=C1CC(O)CC2 IKPRVTAASFTTOZ-UHFFFAOYSA-N 0.000 description 1
- MLNGSUAMEKZCKV-UHFFFAOYSA-N O=C(NCC1=CC(N2CCC(CO)CC2)=C(C(F)(F)F)C=C1)NC1=CC=CC2=C1CC(O)CC2 Chemical compound O=C(NCC1=CC(N2CCC(CO)CC2)=C(C(F)(F)F)C=C1)NC1=CC=CC2=C1CC(O)CC2 MLNGSUAMEKZCKV-UHFFFAOYSA-N 0.000 description 1
- YLIZAPUBDWCSLQ-UHFFFAOYSA-N O=C(NCC1=CC(N2CCCC2)=C(C(F)(F)F)C=C1)NC1=CC=CC2=C1CC(O)CC2 Chemical compound O=C(NCC1=CC(N2CCCC2)=C(C(F)(F)F)C=C1)NC1=CC=CC2=C1CC(O)CC2 YLIZAPUBDWCSLQ-UHFFFAOYSA-N 0.000 description 1
- GVWNEEGFMKOICT-UHFFFAOYSA-N O=C(NCC1=CC(N2CCCCCC2)=C(C(F)(F)F)C=C1)NC1=CC=CC2=C1CC(O)CC2 Chemical compound O=C(NCC1=CC(N2CCCCCC2)=C(C(F)(F)F)C=C1)NC1=CC=CC2=C1CC(O)CC2 GVWNEEGFMKOICT-UHFFFAOYSA-N 0.000 description 1
- FZGQQLUZXINLTQ-UHFFFAOYSA-N O=C(NCC1=CC(N2CCNCC2)=C(C(F)(F)F)C=C1)NC1=CC=CC2=C1CC(O)CC2 Chemical compound O=C(NCC1=CC(N2CCNCC2)=C(C(F)(F)F)C=C1)NC1=CC=CC2=C1CC(O)CC2 FZGQQLUZXINLTQ-UHFFFAOYSA-N 0.000 description 1
- OMGHINILXXQOTJ-UHFFFAOYSA-N O=C(NCC1=CC=C(C(F)(F)F)C(N2CCC(O)CC2)=C1)NC1=CC=CC2=C1CC(O)CC2 Chemical compound O=C(NCC1=CC=C(C(F)(F)F)C(N2CCC(O)CC2)=C1)NC1=CC=CC2=C1CC(O)CC2 OMGHINILXXQOTJ-UHFFFAOYSA-N 0.000 description 1
- YLIZAPUBDWCSLQ-KRWDZBQOSA-N O=C(NCC1=CC=C(C(F)(F)F)C(N2CCCC2)=C1)NC1=CC=CC2=C1C[C@@H](O)CC2 Chemical compound O=C(NCC1=CC=C(C(F)(F)F)C(N2CCCC2)=C1)NC1=CC=CC2=C1C[C@@H](O)CC2 YLIZAPUBDWCSLQ-KRWDZBQOSA-N 0.000 description 1
- DGESMSFNPOXITK-UHFFFAOYSA-N O=C(NCC1=CC=C(C(F)(F)F)C(N2CCOCC2)=C1)NC1=CC=CC2=C1CC(O)CC2 Chemical compound O=C(NCC1=CC=C(C(F)(F)F)C(N2CCOCC2)=C1)NC1=CC=CC2=C1CC(O)CC2 DGESMSFNPOXITK-UHFFFAOYSA-N 0.000 description 1
- DGESMSFNPOXITK-QGZVFWFLSA-N O=C(NCC1=CC=C(C(F)(F)F)C(N2CCOCC2)=C1)NC1=CC=CC2=C1C[C@H](O)CC2 Chemical compound O=C(NCC1=CC=C(C(F)(F)F)C(N2CCOCC2)=C1)NC1=CC=CC2=C1C[C@H](O)CC2 DGESMSFNPOXITK-QGZVFWFLSA-N 0.000 description 1
- XSRINNSJNWBIJX-UHFFFAOYSA-N O=C(NCC1=CC=C(N2CCCC2)C(C(F)(F)F)=C1)NC1=CC=CC2=C1CC(O)CC2 Chemical compound O=C(NCC1=CC=C(N2CCCC2)C(C(F)(F)F)=C1)NC1=CC=CC2=C1CC(O)CC2 XSRINNSJNWBIJX-UHFFFAOYSA-N 0.000 description 1
- OLTUCRIIFLTDAD-UHFFFAOYSA-N O=C(NCC1=CC=C(N2CCCC2)C=C1)NC1=CC=CC2=C1CC(O)CC2 Chemical compound O=C(NCC1=CC=C(N2CCCC2)C=C1)NC1=CC=CC2=C1CC(O)CC2 OLTUCRIIFLTDAD-UHFFFAOYSA-N 0.000 description 1
- XODLYWCXAIVHTN-UHFFFAOYSA-N O=C(NCC1=CC=C(N2CCCCC2)C(Br)=C1)NC1=CC=CC2=C1CC(O)CC2 Chemical compound O=C(NCC1=CC=C(N2CCCCC2)C(Br)=C1)NC1=CC=CC2=C1CC(O)CC2 XODLYWCXAIVHTN-UHFFFAOYSA-N 0.000 description 1
- MADBYHVATOBJPL-UHFFFAOYSA-N O=C(NCC1=CC=C(N2CCCCC2)C(C(F)(F)F)=C1)NC1=CC=CC2=C1CC(O)CC2 Chemical compound O=C(NCC1=CC=C(N2CCCCC2)C(C(F)(F)F)=C1)NC1=CC=CC2=C1CC(O)CC2 MADBYHVATOBJPL-UHFFFAOYSA-N 0.000 description 1
- OPJLMAPCALMVQM-UHFFFAOYSA-N O=C(NCC1=CC=C(N2CCCCC2)C=C1)NC1=CC=CC2=C1CC(O)CC2 Chemical compound O=C(NCC1=CC=C(N2CCCCC2)C=C1)NC1=CC=CC2=C1CC(O)CC2 OPJLMAPCALMVQM-UHFFFAOYSA-N 0.000 description 1
- GDBDMXZQHLIKDD-UHFFFAOYSA-N O=C(NCC1=CC=C(N2CCN(CC3=CC=CC=C3)CC2)C=C1)NC1=C2CC(O)CCC2=CC=C1 Chemical compound O=C(NCC1=CC=C(N2CCN(CC3=CC=CC=C3)CC2)C=C1)NC1=C2CC(O)CCC2=CC=C1 GDBDMXZQHLIKDD-UHFFFAOYSA-N 0.000 description 1
- MUXKISLCIKUMFX-UHFFFAOYSA-N O=C(NCC1=CC=C(N2CCOCC2)C=C1)NC1=CC=CC2=C1CC(O)CC2 Chemical compound O=C(NCC1=CC=C(N2CCOCC2)C=C1)NC1=CC=CC2=C1CC(O)CC2 MUXKISLCIKUMFX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Definitions
- the present invention relates to a tetrahydro-naphthalene derivative which is useful as an active ingredient of pharmaceutical preparations.
- the tetrahydro-naphthalene derivative of the present invention has vanilloid receptor (VR) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of overactive bladder, urinary incontinence such as urge urinary incontinence, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, and inflammatory disorders such as asthma and chronic obstructive pulmonary (or airways) disease (COPD).
- VR vanilloid receptor
- Vanilloid compounds are characterized by the presence of vanillyl group or a functionally equivalent group.
- vanilloid compounds or vanilloid receptor modulators are vanillin (4-hydroxy-3-methoxy-benzaldehyde), guaiacol (2-methoxy-phenol), zingerone (4-/4-hydroxy-3-methoxyphenyl/-2-butanon), eugenol(2-methoxy-4-/2-propenyl/phenol), and capsaicin (8-methyl-N-vanillyl-6-noneneamide).
- capsaicin the main pungent ingredient in “hot” chili peppers, is a specific neurotoxin that desensitizes C-fiber afferent neurons.
- Capsaicin interacts with vanilloid receptors (VR), which are predominantly expressed in cell bodies of dorsal root ganglia (DRG) or nerve endings of afferent sensory fibers including C-fiber nerve endings [Tominaga M, Caterina M J, Malmberg A B, Rosen T A, Gilbert H, Skinner K, Raumann B E, Basbaum A I, Julius D: The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron. 21: 531-543, 1998].
- the VR1 receptor was recently cloned.
- antagonists of the VR1 receptor can be used for prophylaxis and treatment of the condition and diseases including chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, urinary incontinence (UI) such as urge urinary incontinence (UUI), and/or overactive bladder.
- UI urinary incontinence
- UUI urge urinary incontinence
- UUI is the involuntary loss of urine.
- UUI is one of the most common types of UI together with stress urinary incontinence (SUI) which is usually caused by a defect in the urethral closure mechanism.
- UI is often associated with neurological disorders or diseases causing neuronal damages such as dementia, Parkinson's disease, multiple sclerosis, stroke and diabetes, although it also occurs in individuals with no such disorders.
- SAI stress urinary incontinence
- OAB overactive bladder
- WO 00/50387 discloses the compounds having a vanilloid agonist activity represented by the general formula:
- WO 2000/61581 discloses amine derivatives represented by the general formula:
- WO 00/75106 discloses the compounds represented by the general formula:
- WO 00/55152 discloses the compounds represented by the general formula:
- Ar 1 is heterocycle
- Ar 2 is tetrahydronapthyl
- X 0 is O or S
- L and Q are defined in this specification; as useful agents for treating inflammation, immune related disease, pain and diabetes.
- This invention is to provide a tetrahydro-naphthalene derivatives of the formula (I), their tautomeric and stereoisomeric form, and salts thereof:
- the compounds of the present invention are also effective for treating or preventing a disease selected from the group consisting of chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration and/or stroke, as well as inflammatory diseases such as asthma and COPD since the diseases also relate to VR1 activity.
- a disease selected from the group consisting of chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration and/or stroke, as well as inflammatory diseases such as asthma and COPD since the diseases also relate to VR1 activity.
- the compounds of the present invention are useful for the treatment of musculoskeletal pain, forms of pain often associated with osteoarthritis or rheumatoid arthritis or other forms of arthritis, and back pain.
- the compounds of the present invention are useful for the treatment of pain associated with cancer, including visceral or neuropathic pain associated with cancer or cancer treatment.
- the compounds of the present invention are furthermore useful for the treatment of visceral pain, e.g. pain associated with obstruction of hollow viscus like gallstone colik, pain associated with irritable bowel syndrome, pelvic pain, vulvodynia, orchialgia or prostatodynia, pain associated with inflammatory lesions of joints, skin, muscles or nerves, and orofascial pain and headache, e.g. migraine or tension-type headache.
- visceral pain e.g. pain associated with obstruction of hollow viscus like gallstone colik
- pain associated with irritable bowel syndrome pelvic pain
- vulvodynia orchialgia or prostatodynia
- pain associated with inflammatory lesions of joints, skin, muscles or nerves e.g. migraine or tension-type headache.
- tetrahydro-napththalene derivatives of formula (I) are those wherein;
- said tetrahydro-naphthalene derivative of the formula (I) is selected from the group consisting of:
- the present invention provides a medicament, which includes one of the compounds, described above and optionally pharmaceutically acceptable excipients.
- Alkyl per se and “alk” and “alkyl” in alkenyl, alkynyl, alkoxy, alkanoyl, alkylamino, alkylaminocarbonyl, alkylaminosulphonyl, alkylsulphonylamino, alkoxycarbonyl, alkoxycarbonylamino and alkanoylamino represent a linear or branched alkyl radical having generally 1 to 6, preferably 1 to 4 and particularly preferably 1 to 3 carbon atoms, representing illustratively and preferably methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-pentyl and n-hexyl.
- Alkoxy illustratively and preferably represents methoxy, ethoxy, n-propoxy, isopropoxy, tert-butoxy, n-pentoxy and n-hexoxy.
- Alkylamino illustratively and preferably represents an alkylamino radical having one or two (independently selected) alkyl substituents, illustratively and preferably representing methylamino, ethylamino, n-propylamino, isopropylamino, tert-butylamino, n-pentylamino, n-hexyl-amino, N,N-dimethylamino, N,N-diethylamino, Nethyl-N-methylamino, N-methyl-N-n-propylamino, N-isopropyl-N-n-propylamino, N-t-butyl-N-methylamino, N-ethyl-N-n-pentylamino and N-n-hexyl-N-methylamino.
- Heterocycle and/or heterocyclic as used herein designate a closed ring structure, in which one or more of the atoms in the ring is a heteroatom such as sulfur, nitrogen, oxygen, and the like.
- Suitable examples include, without limitation, pyrrolidinyl, piperidino, piperazinyl homopiperidino, morpholinyl, thiomorpholinyl, tetrahydrofuryl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, pyridyl pyrazinyl, pyrimidyl, pyridazinyl and the like.
- the compound of the formula (I) of the present invention can be, but not limited to be, prepared by combining various known methods.
- one or more of the substituents, such as amino group, carboxyl group, and hydroxyl group of the compounds used as starting materials or intermediates are advantageously protected by a protecting group known to those skilled in the art. Examples of the protecting groups are described in “Protective Groups in Organic Synthesis (3rd Edition)” by Greene and Wuts, John Wiley and Sons, New York 1999.
- the compound of the formula (I) (wherein n, R 1 , R 2 , R 3 , and R 4 are the same as defined above) can be prepared by reacting the compound of the formula (II) (wherein R 1 is the same as defined above) and the compound of the formula (III) (wherein L 1 represents halogen atom such as chlorine, bromine, or iodine atom) and then adding the compound of the formula (IV) (wherein n, R 2 , R 3 , and R 4 are the same as defined above) to the reaction mixture.
- the reaction may be carried out in a solvent including, for instance, halogenated hydrocarbons such as dichloromethane, chloroform and 1,2-dichloroethane; ethers such as diethyl ether, isopropyl ether, dioxane and tetrahydrofuran (THF) and 1,2-dimethoxyethane; aromatic hydrocarbons such as benzene, toluene and xylene; nitriles such as acetonitrile; amides such as N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMAC) and N-methylpyrrolidone (NMP); urea such as 1,3-dimethyl-2-imidazolidinone (DMI); sulfoxides such as dimethylsulfoxide (DMSO); and others.
- a solvent including, for instance, halogenated hydrocarbons such as dichloromethane, chloroform and 1,2-dichloroethan
- the reaction temperature can be optionally set depending on the compounds to be reacted.
- the reaction temperature is usually, but not limited to, about 20° C. to 50° C.
- the reaction may be conducted for, usually, 30 minutes to 10 hours and preferably 1 to 24 hours.
- the reaction can be advantageously carried out in the presence of a base including, for instance, organic amines such as pyridine, triethylamine and N,N-diisopropylethylamine, dimethylaniline, diethylaniline, 4-dimethylaminopyridine, and others.
- a base including, for instance, organic amines such as pyridine, triethylamine and N,N-diisopropylethylamine, dimethylaniline, diethylaniline, 4-dimethylaminopyridine, and others.
- the compound (II) and (IV) are commercially available or can be prepared by the use of known techniques.
- the compound of the formula (I) (wherein n, R 1 , R 2 , R 3 , and R 4 are the same as defined above) can be prepared by the reaction of the compound of the formula (II) (wherein R 1 is the same as defined above) and the compound of the formula (V) (wherein n, R 2 , R 3 and R 4 are the same as defined above).
- the reaction may be carried out in a solvent including, for instance, halogenated hydrocarbons such as dichloromethane, chloroform and 1,2-dichloroethane; ethers such as diethyl ether, isopropyl ether, dioxane and tetrahydrofuran (THF) and 1,2-dimethoxyethane; aromatic hydrocarbons such as benzene, toluene and xylene; nitriles such as acetonitrile; amides such as N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMAC) and N-methylpyrrolidone NP); urea such as 1,3-dimethyl-2-imidazolidinone (DMI); sulfoxides such as dimethylsulfoxide (DMSO); and others.
- a solvent including, for instance, halogenated hydrocarbons such as dichloromethane, chloroform and 1,2-dichloroethane
- the reaction can be carried out in the presence of organic base such as pyridine or triethylamine.
- the reaction temperature can be optionally set-depending on the compounds to be reacted.
- the reaction temperature is usually, but not limited to, about room temperature to 100° C.
- the reaction may be conducted for, usually, 30 minutes to 48 hours and preferably 1 to 24 hours.
- the compound (V) can be prepared by the use of known techniques or are commercially available.
- the compound of the formula (I) (wherein n, R 1 , R 2 , R 3 , and R 4 are the same as defined above) can be prepared by reacting the compound of the formula (II) (wherein R 1 is the same as defined above) with phosgene, diphosgene, triphosgene, 1,1-carbonyldiimidazole (CDI), or 1,1′-carbonyldi(1,2,4-triazole)(CDT), and then adding the compound of the formula (I) (wherein n, R 2 , R 3 , and R 4 are the same as defined above) to the reaction mixture.
- the reaction may be carried out in a solvent including, for instance, halogenated hydrocarbons such as dichloromethane, chloroform and 1,2-dichloroethane; ethers such as diethyl ether, isopropyl ether, dioxane and tetrahydrofuran (THF) and 1,2-dimethoxyethane; aromatic hydrocarbons such as benzene, toluene and xylene; nitrites such as acetonitrile; amides such as N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMAC) and N-methylpyrrolidone (NMP); urea such as 1,3-dimethyl-2-imidazolidinone (DMI; sulfoxides such as dimethylsulfoxide (DMSO); and others.
- a solvent including, for instance, halogenated hydrocarbons such as dichloromethane, chloroform and 1,2-dichloroethan
- the reaction temperature can be optionally set depending on the compounds to be reacted.
- the reaction temperature is usually, but not limited to, about 20° C. to 50° C.
- the reaction may be conducted for, usually, 30 minutes to 10 hours and preferably 1 to 24 hours.
- Phosgene, diphosgene, triphosgene, CDI, and CDT are commercially available.
- the compound of the formula (I) (wherein n, R 1 , R 2 , R 3 and R 4 are the same as defined above) can be prepared by reacting the compound of the formula (IV) (wherein n, R 2 , R 3 , and R 4 are the same as defined above) with phosgene, diphosgene, triphosgene, 1,1-carbonyldiimidazole (CDI), or 1,1′-carbonyldi(1,2,4-triazole) (CDT) and then adding the compound of the formula (II) (wherein R 1 is the same as defined above) to the reaction mixture.
- the reaction may be carried out in a solvent including, for instance, halogenated hydrocarbons such as dichloromethane, chloroform and 1,2-dichloroethane; ethers such as diethyl ether, isopropyl ether, dioxane and tetrahydrofuran (THF) and 1,2-dimethoxyethane; aromatic hydrocarbons such as benzene, toluene and xylene; nitriles such as acetonitrile; amides such as N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMAC) and N-methylpyrrolidone (NMP); urea such as 1,3-dimethyl-2-imidazolidinone (DMI); sulfoxides such as dimethylsulfoxide (DMSO); and others.
- a solvent including, for instance, halogenated hydrocarbons such as dichloromethane, chloroform and 1,2-dichloroethan
- the reaction temperature can be optionally set depending on the compounds to be reacted.
- the reaction temperature is usually, but not limited to, about 20° C. to 50° C.
- the reaction may be conducted for, usually, 30 minutes to 10 hours and preferably 1 to 24 hours.
- the compound of the formula (I) (wherein n, R 1 , R 2 , R 3 and R 4 are the same as defined above) can be prepared by reacting the compound of the formula (IV) (Wherein n, R 2 , R 3 , and R 4 are the same as defined above) and the compound of the formula (III) (wherein L 1 is the same as defined above), and then adding the compound of the formula (II) (wherein R 1 is the same as defined above) to the reaction mixture.
- the reaction may be carried out in a solvent including, for instance, halogenated hydrocarbons such as dichloromethane, chloroform and 1,2-dichloroethane; ethers such as diethyl ether, isopropyl ether, dioxane and tetrahydrofuran (THF) and 1,2-dimethoxyethane; aromatic hydrocarbons such as benzene, toluene and xylene; nitrites such as acetonitrile; amides such as N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMAC) and N-methylpyrrolidone (NMP); urea such as 1,3-dimethyl-2-imidazolidinone (DM); sulfoxides such as dimethylsulfoxide (DMSO); and others.
- a solvent including, for instance, halogenated hydrocarbons such as dichloromethane, chloroform and 1,2-dichloroethane
- the reaction temperature can be optionally set depending on the compounds to be reacted.
- the reaction temperature is usually, but not limited to, about 20° C. to 50° C.
- the reaction may be conducted for, usually, 30 minutes to 10 hours and preferably 1 to 24 hours.
- the reaction can be advantageously carried out in the presence of a base including, for instance, organic amines such as pyridine, triethylamine and N,N-diisopropylethylamine, dimethylaniline, diethylamine, 4-dimethylaminopyridine, and others.
- a base including, for instance, organic amines such as pyridine, triethylamine and N,N-diisopropylethylamine, dimethylaniline, diethylamine, 4-dimethylaminopyridine, and others.
- the compound of the formula (VII) (wherein n, R 1 , R 2 , R 3 and R 4 are the same as defined above) can be prepared by reacting the compound of the formula (VI) (wherein R 1 is the same as defined above) with the compound of the formula (V) (wherein n, R 2 , R 3 and R 4 are the same as defined above) in a similar manner described in Method B for the preparation of the compound of the formula (I).
- the compound of the formula (VIII) (wherein n, R 1 , R 2 , R 3 , and R 4 are the same as defined above) can be prepared by reacting the compound of the formula (VII) (wherein n, R 1 , R 2 , R 3 , and R 4 are the same as defined above) with an acid such as hydrochloric acid.
- the reaction may be carried out in a solvent including, for instance, halogenated hydrocarbons such as dichloromethane, chloroform and 1,2-dichloroethane; ethers such as diethyl ether, isopropyl ether, dioxane and tetrahydrofuran (THF) and 1,2-dimethoxyethane; alcohols such as methanol, ethanol; water and others.
- halogenated hydrocarbons such as dichloromethane, chloroform and 1,2-dichloroethane
- ethers such as diethyl ether, isopropyl ether, dioxane and tetrahydrofuran (THF) and 1,2-dimethoxyethane
- alcohols such as methanol, ethanol; water and others.
- two or more of the solvents selected from the listed above can be mixed and used.
- the reaction temperature can be optionally set depending on the compounds to be reacted.
- the reaction temperature is usually, but not limited to, about 20° C. to 10° C.
- the reaction may be conducted for, usually, 30 minutes to 10 hours and preferably 1 to 24 hours.
- the compound of the formula (I) (wherein n, R 1 , R 2 , R 3 and R 4 are the same as defined above) can be prepared by reacting the compound of the formula (VIII) (wherein n, R 1 , R 2 , R 3 and R 4 are the same as defined above) with reducing agent such as sodium borohydride or lithium aluminum hydride.
- the reaction may be carried out in a solvent including, for instance, ethers such as diethyl ether, isopropyl ether, dioxane and tetrahydrofuran (THF) and 1,2-dimethoxyethane; alcohols such as methanol, ethanol, isopropanol, and others.
- ethers such as diethyl ether, isopropyl ether, dioxane and tetrahydrofuran (THF) and 1,2-dimethoxyethane
- alcohols such as methanol, ethanol, isopropanol, and others.
- two or more of the solvents selected from the listed above can be mixed and used.
- the reaction temperature can be optionally set depending on the compounds to be reacted.
- the reaction temperature is usually, but not limited to, about 20° C. to 50° C.
- the reaction may be conducted for, usually, 30 minutes to 10 hours and preferably 1 to 24 hours.
- the compound (VI) is commercially available or can be prepared by the use of known techniques.
- the compound of the formula (I) (wherein n, R 1 , R 2 , R 3 and R 4 are the same as defined above) can be obtained by the reaction of the compound of the formula (X) (wherein n, R 1 , R 2 , R 3 , R 4 and L are the same as defined above) with the compound of the formula (IX) (wherein R 2 and R 3 are the same as defined above).
- the reaction may be carried out in a solvent including, for instance, ethers such as diethyl ether, isopropyl ether, dioxane and tetrahydrofuran (THF) and 1,2-dimethoxyethane; aromatic hydrocarbons such as benzene, toluene and xylene; amides such as N,N-dimethylformamide (DMF), N,N-dimethylacetamide and N-methylpyrrolidone; sulfoxides such as dimethylsulfoxide (DMSO); alcohols such as methanol, ethanol, 1-propanol, isopropanol and tert-butanol; water and others.
- ethers such as diethyl ether, isopropyl ether, dioxane and tetrahydrofuran (THF) and 1,2-dimethoxyethane
- aromatic hydrocarbons such as benzene, toluene and xylene
- the reaction can be advantageously carried out in the presence of an catalyst such as palladium catalysts and others.
- the reaction temperature can be optionally set depending on the compounds to be reacted.
- the reaction temperature is usually, but not limited to, about 20° C. to 120° C.
- the reaction may be conducted for, usually, 30 minutes to 60 hours and preferably 1 to 48 hours.
- the compound (X) can be prepared in a similar manner as described in Method [A], [B], [C], [D], [E], or [F] for the preparation of the compound of the formula (I) using a compound
- the stereoisomeric form of the compound (I), R form (I-i) (wherein n, R 1 , R 2 , R 3 , and R 4 are the same as defined above) can be prepared by the reaction of the compound of the formula (II-i) (wherein R 1 is the same as defined above) with the compound of the formula (V) (wherein n, R 2 , R 3 , and R 4 are the same as defined above) in a similar manner described in Method. B for the preparation of the compound of the formula (I).
- the stereoisomeric form of the compound (I), S form (I-ii) (wherein n, R 1 , R 2 , R 3 , and R 4 are the same as defined above) can be prepared by the reaction of the compound of (II-ii) (wherein R 1 is the same as defined above) with the compound of the formula (V) (wherein n, R 1 , R 2 , R 3 , and R 4 are the same as defined above) in a similar manner described in Method B for the preparation of the compound of the formula (I).
- the compound (II-i) or (II-ii) can be prepared by the use of known techniques.
- Typical salts of the compound shown by the formula (I) include salts prepared by reaction of the compounds of the present invention with a mineral or organic acid, or an organic or inorganic base. Such salts are known as acid addition and base addition salts, respectively.
- Acids to form acid addition salts include inorganic acids such as, without limitation, sulfuric acid, phosphoric acid, hydrochloric acid, hydrobromic acid, hydriodic acid and the like, and organic acids, such as, without limitation, p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like.
- inorganic acids such as, without limitation, sulfuric acid, phosphoric acid, hydrochloric acid, hydrobromic acid, hydriodic acid and the like
- organic acids such as, without limitation, p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like.
- Base addition salts include those derived from inorganic bases, such as, without limitation, ammonium hydroxide, alkaline metal hydroxide, alkaline earth metal hydroxides, carbonates, bicarbonates, and the like, and organic bases, such as, without limitation, ethanolamine, triethylamine, tris(hydroxymethyl)aminomethane, and the like.
- inorganic bases include sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate, calcium hydroxide, calcium carbonate, and the like.
- the compound of the present invention or a salt thereof, depending on its substituents, may be modified to form lower alkylesters or known other esters; and/or hydrates or other solvates. Those esters, hydrates, and solvates are included in the scope of the present invention.
- the compound of the present invention may be administered in oral forms, such as, without limitation normal and enteric coated tablets, capsules, pills, powders, granules, elixirs, tinctures, solution, suspensions, syrups, solid and liquid aerosols and emulsions. They may also be administered in parenteral forms, such as, without limitation, intravenous, intraperitoneal, subcutaneous, intramuscular, and the like forms, well-known to those of ordinary skill in the pharmaceutical arts.
- the compounds of the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using trans-dermal delivery systems well-known to those of ordinary skilled in the art.
- the dosage regimen with the use of the compounds of the present invention is selected by one of ordinary skill in the arts, in view of a variety of factors, including, without limitation, age, weight, sex, and medical condition of the recipient, the severity of the condition to be treated, the route of administration, the level of metabolic and excretory function of the recipient, the dosage form employed, the particular compound and salt thereof employed
- the compounds of the present invention are preferably formulated prior to administration together with one or more pharmaceutically-acceptable excipients.
- Excipients are inert substances such as, without limitation carriers, diluents, flavoring agents, sweeteners, lubricants, solubilizers, suspending agents, binders, tablet disintegrating agents and encapsulating material.
- compositions of the present invention are pharmaceutical formulation comprising a compound of the invention and one or more pharmaceutically-acceptable excipients that are compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
- Pharmaceutical formulations of the invention are prepared by combining a therapeutically effective amount of the compounds of the invention together with one or more pharmaceutically-acceptable excipients therefore.
- the active ingredient may be mixed with a diluent, or enclosed within a carrier, which may be in the form of a capsule, sachet, paper, or other container.
- the carrier may serve as a diluent, which may be solid, semi-solid, or liquid material which acts as a vehicle, or can be in the form of tablets, pills powders, lozenges, elixirs, suspensions, emulsions, solutions, syrups, aerosols, ointments, containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders.
- a diluent which may be solid, semi-solid, or liquid material which acts as a vehicle, or can be in the form of tablets, pills powders, lozenges, elixirs, suspensions, emulsions, solutions, syrups, aerosols, ointments, containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders.
- the active ingredient may be combined with an oral, and non-toxic, pharmaceutically-acceptable carrier, such as, without limitation, lactose, starch, sucrose, glucose, sodium carbonate, mannitol, sorbitol, calcium carbonate, calcium phosphate, calcium sulfate, methyl cellulose, and the like; together with, optionally, disintegrating agents, such as, without limitation, maize, starch, methyl cellulose, agar bentonite, xanthan gum, alginic acid, and the like; and optionally, binding agents, for example, without limitation, gelatin, natural sugars, beta-lactose, corn sweeteners, natural and synthetic gums, acacia, tragacanth, sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like; and, optionally, lubricating agents, for example, without limitation, magnesium stearate, sodium stearate, stearic acid, sodium oleate, sodium benzoate,
- the carrier may be a finely divided solid which is in admixture with the finely divided active ingredient.
- the active ingredient may be mixed with a carrier having binding properties in suitable proportions and compacted in the shape and size desired to produce tablets.
- the powders and tablets preferably contain from about 1 to about 99 weight percent of the active ingredient which is the novel composition of the present invention.
- Suitable solid carriers are magnesium carboxymethyl cellulose, low melting waxes, and cocoa butter.
- Sterile liquid formulations include suspensions, emulsions, syrups and elixirs.
- the active ingredient can be dissolved or suspended in a pharmaceutically acceptable carriers, such as sterile water, sterile organic solvent, or a mixture of both sterile water and sterile organic solvent.
- the active ingredient can also be dissolved in a suitable organic solvent, for example, aqueous propylene glycol.
- a suitable organic solvent for example, aqueous propylene glycol.
- Other compositions can be made by dispersing the finely divided active ingredient in aqueous starch or sodium carboxymethyl cellulose solution or in a suitable oil.
- the formulation may be in unit dosage form, which is a physically discrete unit containing a unit dose, suitable for administration in human or other mammals.
- a unit dosage form can be a capsule or tablets, or a number of capsules or tablets.
- a “unit dose” is a predetermined quantity of the active compound of the present invention, calculated to produce the desired therapeutic effect, in association with one or more excipients.
- the quantity of active ingredient in a unit dose may be varied or adjusted from about 0.1 to about 1000 milligrams or more according to the particular treatment involved.
- Typical oral dosages of the present invention when used for the indicated effects, will range from about 0.01 mg/kg/day to about 100 mg/kg/day, preferably from 0.1 mg/kg/day to 30 mg/kg/day, and most preferably from about 0.5 mg/kg/day to about 10 mg/kg/day.
- parenteral administration it has generally proven advantageous to administer quantities of about 0.001 to 100 mg/kg/day, preferably from 0.01 mg/kg/day to 1 mg/kg/day.
- the compounds of the present invention may be administered in a single daily dose, or the total daily dose may be administered in divided doses, two, three, or more times per day. Where delivery is via transdermal forms, of course, administration is continuous.
- Mass spectra were obtained using electrospray (ES) ionation techniques (micromass Platform LC). Melting points are uncorrected.
- Liquid Chromatography—Mass spectroscopy (LC-MS) data were recorded on a Micromass Platform LC with Shimadzu Phenomenex ODS column (4.6 mm ⁇ 30 mm) flushing a mixture of acetonitrile-water (9:1 to 1:9) at 1 ml/min of the flow rate.
- TLC was performed on a precoated silica gel plate (Merck silica gel 60 F-254). Silica gel (WAKO-gel C-200 (75-150 ⁇ m)) was used for all column chromatography separations.
- Human vanilloid receptor (hVR1) cDNA was cloned from libraries of axotomized dorsal root ganglia (WO 00/29577). The cloned hVR1 cDNA was constructed with pcDNA3 vector and transfected into a CHOluc9aeq cell line. The cell line contains aequorin and CRE-luciferase reporter genes as read-out signals.
- the transfectants were cloned by limiting dilution in selection medium (DMEM/F12 medium (Gibco BRL) supplemented with 10% FCS, 1.4 mM Sodium pyravate, 20 mM HEPES, 0.15% Sodium bicarbonate, 100 U/ml penicillin, 100 ⁇ g/ml streptomycin, 2 mM glutamine, non-essential amino acids and 2 mg/ml G418). Ca 2+ influx was examined in the capsaicin-stimulated clones. A high responder clone was selected and used for further experiments in the project.
- the human VR1-CHOluc9aeq cells were maintained in the selection medium and passaged every 3-4 days at 1-2.5 ⁇ 10 5 cells/flask (75 mm 2 ).
- Human VR1-CHOluc9aeq cells were suspended in a culture medium which is the same as the selection medium except for G418 and seeded at a density of 1,000 cells per well into 384-well plates (black walled clear-base/Nalge Nunc International). Following the culture for 48 hrs the medium was changed to 2 ⁇ M Fluo-3 AM (Molecular Probes) and 0.02% Puronic F-127 in assay buffer (Hank's balanced salt solution (HBSS), 17 mM HEPES (pH7.4), 1 mM Probenecid, 0.1% BSA) and the cells were incubated for 60 min at 25° C. After washing twice with assay buffer the cells were incubated with a test compound or vehicle for 20 min at 25° C.
- assay buffer Hort's balanced salt solution (HBSS), 17 mM HEPES (pH7.4), 1 mM Probenecid, 0.1% BSA
- DRG dorsal root ganglia
- DRG was incubated with 0.1% trypsin (Gibco BRL) in PBS( ⁇ ) (Gibco BRL) for 30 min at 37° C., then a half volume of fetal calf serum (FCS) was added and the cells were spun down.
- FCS fetal calf serum
- the DRG neuron cells were resuspended in Ham F12/5% FCS/5% horse serum (Gibco, BRL) and dispersed by repeated pipetting and passing through 70 m mesh (Falcon). The culture plate was incubated for 3 hours at 37° C. to remove contaminating Schwann cells.
- Non-adherent cells were recovered and further cultured in laminin-coated 384 well plates (Nunc) at 1 ⁇ 10 4 cells/50 ⁇ l/well for 2 days in the presence of 50 ng/ml recombinant rat NGF (Sigma) and 50 ⁇ M 5-fluorodeoxyuridine (Sigma).
- Isometric tension was recorded under a load of 1 g using longitudinal strips of rat detrusor muscle. Bladder strips were equilibrated for 60 min before each stimulation. Contractile response to 80 mM KCl was determined at 15 min intervals until reproducible responses were obtained. The response to KCl was used as an internal standard to evaluate the maximal response to capsaicin. The effects of the compounds were investigated by incubating the strips with compounds for 30 min prior to the stimulation with 1 ⁇ M capsaicin (vehicle: 80% saline, 10% EtOH, and 10% Tween 80). One of the preparations made from the same animal was served as a control while the others were used for evaluating compounds. Ratio of each capsaicin-induced contraction to the internal standard (i.e. KCl-induced contraction) was calculated and the effects of the test compounds on the capsaicin-induced contraction were evaluated.
- Human P2X1-transfected CHOluc9aeq cell line was established and maintained in Dulbecco's modified Eagle's medium (DMEM/F12) supplemented with 7.5% FCS, 0.20 mM HEPES-KOH (pH 7.4), 1.4 mM sodium pyruvate, 100 U/ml penicillin, 100 ⁇ g/ml streptomycin, 2 mM glutamine (Gibco BRL) and 0.5 Units/ml apyrase (grade I, Sigma).
- the suspended cells were seeded in each well of 384-well optical bottom black plates (Nalge Nunc International) at 3 ⁇ 10 3 /50 ⁇ l/well. The cells were cultured for following 48 hrs to adhere to the plates.
- P2X1 receptor agonist-mediated increases in cytosolic Ca 2+ levels were measured using a fluorescent Ca 2+ chelating dye, Fluo-3 AM (Molecular Probes).
- the plate-attached cells were washed twice with washing buffer (HBSS, 17 mM HEPES-KOH (pH 7.4), 0.1% BSA and 0.5 units/ml apyrase), and incubated in 40 ⁇ l of loading buffer (1 ⁇ M Fluo-3 AM, 1 mM probenecid, 1 ⁇ M cyclosporin A, 0.01% pluronic (Molecular Probes) in washing buffer) for 1 hour in a dark place.
- mice Female Sprague-Dawley rats (200 ⁇ 250 g/Charles River Japan) were used.
- Rats were anesthetized by intraperitoneal administration of urethane (Sigma) at 1.2 g/kg.
- the abdomen was opened through a midline incision, and a polyethylene catheter (BECTON DICKINSON, PE50) was implanted into the bladder through the dome.
- a polyethylene catheter (Hibiki, size 5) filled with 2 IU/ml of heparin (Novo Heparin, Aventis Pharma) in saline (Otsuka) was inserted into a common iliac artery.
- the bladder catheter was connected via T-tube to a pressure transducer (Viggo-Spectramed Pte Ltd, DT-XXAD) and a microinjection pump (TERUMO). Saline was infused at room temperature into the bladder at a rate of 2.4 ml/hr. Intravesical pressure was recorded continuously on a chart pen recorder (Yokogawa). At least three reproducible micturition cycles, corresponding to a 20-minute period, were recorded before a test compound administration and used as baseline values.
- the saline infusion was stopped before administrating compounds.
- a testing compound dissolved in the mixture of ethanol, Tween 80 (ICN Biomedicals Inc.) and saline (1:1:8, v/v/v) was administered intraarterially at 10 mg/kg. 2 min after the administration of the compound 10 ⁇ g of capsaicin (Nacalai Tesque) dissolved in ethanol was administered intraarterially.
- capsaicin-induced intravesical pressure were analyzed from the cystometry data.
- the capsaicin-induced bladder pressures were compared with the maximum bladder pressure during micturition without the capsaicin stimulation.
- the testing compounds-mediated inhibition of the increased bladder pressures was evaluated using Student's t-test. A probability level less than 5% was accepted as significant difference.
- Cyclophosphamide (CYP) dissolved in saline was administered intra-peritoneally at 150 mg/kg 48 hours before experiment.
- Rats were anesthetized by intraperitoneal administration of urethane (Sigma) at 1.25 g/kg. The abdomen was opened through a midline incision, and a polyethylene catheter (BECTON DICKINSON, PE50) was implanted into the bladder through the dome. In parallel, the inguinal region was incised, and a polyethylene catheter (BECTON DICKINSON, PE50) filled with saline (Otsuka) was inserted into a femoral vein. After the bladder was emptied, the rats were left for 1 hour for recovery from the operation.
- urethane Sigma
- the bladder catheter was connected via T-tube to a pressure transducer (Viggo-Spectramed Pte Ltd, DT-XXAD) and a microinjection pump (TERUMO). Saline was infused at room temperature into the bladder at a rate of 3.6 ml/hr for 20 min. Intravesical pressure was recorded continuously on a chart pen recorder (Yokogawa). At least three reproducible micturition cycles, corresponding to a 20-minute-period, were recorded before a test compound administration.
- a testing compound dissolved in the mixture of ethanol, Tween 80 (ICN Biomedicals Inc.) and saline (1:1:8, v/v/v) was administered intravenously at 0.05 mg/kg, 0.5 mg/kg or 5 mg/kg. 3 min after the administration of the compound, saline (Nacalai Tesque) was infused at room temperature into the bladder at a rate of 3.6 ml/hr.
- the cystometry parameters were analyzed as described previously [Lecci A et al: Eur. J. Pharmacol. 259: 129-135, 1994].
- the micturition frequency calculated from micturition interval and the bladder capacity calculated from a volume of infused saline until the first micturition were analyzed from the cystometry data.
- the testing compounds mediated inhibition of the frequency and the testing compounds—mediated increase of bladder capacity were evaluated using unpaired Student's t-test. A probability levels less than 5% was accepted as significant difference. Data were analyzed as the mean ⁇ SEM from 4-7 rats.
- Acute pain is measured on a hot plate mainly in rats.
- Two variants of hot plate testing are used: In the classical variant animals are put on a hot surface (52 to 56° C.) and the latency time is measured until the animals show nociceptive behavior, such as stepping or foot licking.
- the other variant is an increasing temperature hot plate where the experimental animals are put on a surface of neutral temperature. Subsequently this surface is slowly but constantly heated until the animals begin to lick a hind paw. The temperature which is reached when hind paw licking begins is a measure for pain threshold.
- Compounds are tested against a vehicle treated control group. Substance application is performed at different time points via different application routes (i.v., i.p., p.o., i.t., i.c.v., S.C., intradermal, transdermal) prior to pain testing.
- application routes i.v., i.p., p.o., i.t., i.c.v., S.C., intradermal, transdermal
- Persistent pain is measured with the formalin or capsaicin test, mainly in rats.
- a solution of 1 to 5% formalin or 10 to 100 ⁇ g capsaicin is injected into one hind paw of the experimental animal.
- the animals show nociceptive reactions like flinching, licking and biting of the affected paw.
- the number of nociceptive reactions within a time frame of up to 90 minutes is a measure for intensity of pain.
- Compounds are tested against a vehicle treated control group. Substance application is performed at different time points via different application routes (i.v., i.p., p.o., i.t., i.c.v., s.c., intradermal, transdermal) prior to formalin or capsaicin administration.
- application routes i.v., i.p., p.o., i.t., i.c.v., s.c., intradermal, transdermal
- Neuropathic pain is induced by different variants of unilateral sciatic nerve injury mainly in rats.
- the operation is performed under anesthesia.
- the first variant of sciatic nerve injury is produced by placing loosely constrictive ligatures around the common sciatic nerve (Bennett and Xie, Pain 33 (1988): 87-107).
- the second variant is the tight ligation of about the half of the diameter of the common sciatic nerve (Seltzer et al., Pain 43 (1990): 205-218).
- a group of models is used in which tight ligations or transections are made of either the L5 and L6 spinal nerves, or the L5 spinal nerve only (KIM S H; CHUNG J M, AN EXPERIMENTAL-MODEL FOR PERIPHERAL NEUROPATHY PRODUCED BY SEGMENTAL SPINAL NERVE LIGATION IN THE RA, PAIN 50 (3) (1992): 355-363).
- the fourth variant involves an axotomy of two of the three terminal branches of the sciatic nerve (tibial and common peroneal nerves) leaving the remaining sural nerve intact whereas the last variant comprises the axotomy of only the tibial branch leaving the sural and common nerves uninjured. Control animals are treated with a sham operation.
- the nerve injured animals develop a chronic mechanical allodynia, cold allodynioa, as well as a thermal hyperalgesia.
- Mechanical allodynia is measured by means of a pressure transducer (electronic von Frey Anesthesiometer, IITC Inc.—Life Science Instruments, Woodland Hills, SA, USA; Electronic von Frey System, Somedic Sales AB, Hörby, Sweden).
- Thermal hyperalgesia is measured by means of a radiant heat source (Plantar Test, Ugo Basile, Comerio, Italy), or by means of a cold plate of 5 to 10° C. where the nocifensive reactions of the affected hind paw are counted as a measure of pain intensity.
- a further test for cold induced pain is the counting of nocifensive reactions, or duration of nocifensive responses after plantar administration of acetone to the affected hind limb.
- Chronic pain in general is assessed by registering the circadanian rhytms in activity (Surjo and Arndt, (2015) zu GmbH, Cologne, Germany), and by scoring differences in gait (foot print patterns; FOOTPRINTS program, Klapdor et al., 1997. A low cost method to analyse footprint patterns. J. Neurosci. Methods 75, 49-54).
- Substance application is performed at different time points via different application routes (i.v., i.p., p.o., i.t., i.c.v., S.C., intradermal, transdermal) prior to pain testing.
- application routes i.v., i.p., p.o., i.t., i.c.v., S.C., intradermal, transdermal
- Inflammatory pain is induced mainly in rats by injection of 0.75 mg carrageenan or complete Freund's adjuvant into one hind paw.
- the animals develop an edema with mechanical allodynia as well as thermal hyperalgesia.
- Mechanical allodynia is measured by means of a pressure transducer (electronic von Frey Anesthesiometer, IITC Inc.—Life Science Instruments, Woodland Hills, SA, USA).
- Thermal hyperalgesia is measured by means of a radiant heat source (Plantar Test, Ugo Basile, Comerio, Italy, Paw thermal stimulator, G. Ozaki, University of California, USA).
- Plant Test Ugo Basile, Comerio, Italy
- Paw thermal stimulator G. Ozaki, University of California, USA
- Compounds are tested against uninflamed as well as vehicle treated control groups. Substance application is performed at different time points via different application routes (i.v., i.p., p.o., i.t., i.c.v., s.c., intradermal, transdermal) prior to pain testing.
- application routes i.v., i.p., p.o., i.t., i.c.v., s.c., intradermal, transdermal
- Mechanical allodynia is measured by means of a pressure transducer (electronic von Frey Anesthesiometer, IITC Inc.—Life Science Instruments, Woodland Hills, SA, USA).
- Compounds are tested against diabetic and non-diabetic vehicle treated control groups. Substance application is performed at different time points via different application routes (i.v., i.p., p.o., i.t., i.c.v., s.c., intradermal, transdermal) prior to pain testing.
- application routes i.v., i.p., p.o., i.t., i.c.v., s.c., intradermal, transdermal
- the compounds of the present invention also show excellent selectivity, and strong activity in other assays 2-5 described above.
- tert-butyl (7-hydroxy-1-naphthyl)carbamate (64.0 g, 247 mmol) and cesium carbonate (161 g, 493 mmol) in 300 mL anhydrous DMF was added iodoethane (42.3 g, 272 mmol) at room temperature. The mixture was stirred at 60° C. for 2 hours. Water was added to the mixture, and the product was extracted with ethylacetate. The organic layer was washed with water and brine, dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure. To the obtained residue was added diisopropyl ether and the precipitate was collected and dried to afford tert-butyl (7-ethoxy-1-naphthyl)carbamate (47.9 g, 67.5% yield).
- Example 1-1 compounds in Example 1-2 to 1-28 as shown in Table 1 were synthesized.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
This invention relates to tetrahydro-naphthalene derivatives and salts thereof which is useful as an active ingredient of pharmaceutical preparations. The tetrahydronaphthalene derivatives of the present invention have an excellent activity as VR1 antagonist and useful for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, asthma and COPD.
Description
- The present invention relates to a tetrahydro-naphthalene derivative which is useful as an active ingredient of pharmaceutical preparations. The tetrahydro-naphthalene derivative of the present invention has vanilloid receptor (VR) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of overactive bladder, urinary incontinence such as urge urinary incontinence, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, and inflammatory disorders such as asthma and chronic obstructive pulmonary (or airways) disease (COPD).
- Vanilloid compounds are characterized by the presence of vanillyl group or a functionally equivalent group. Examples of several vanilloid compounds or vanilloid receptor modulators are vanillin (4-hydroxy-3-methoxy-benzaldehyde), guaiacol (2-methoxy-phenol), zingerone (4-/4-hydroxy-3-methoxyphenyl/-2-butanon), eugenol(2-methoxy-4-/2-propenyl/phenol), and capsaicin (8-methyl-N-vanillyl-6-noneneamide).
- Among others, capsaicin, the main pungent ingredient in “hot” chili peppers, is a specific neurotoxin that desensitizes C-fiber afferent neurons. Capsaicin interacts with vanilloid receptors (VR), which are predominantly expressed in cell bodies of dorsal root ganglia (DRG) or nerve endings of afferent sensory fibers including C-fiber nerve endings [Tominaga M, Caterina M J, Malmberg A B, Rosen T A, Gilbert H, Skinner K, Raumann B E, Basbaum A I, Julius D: The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron. 21: 531-543, 1998]. The VR1 receptor was recently cloned. [Caterina M J, Schumacher M A, Torninaga M, Rosen T A, Levine J D, Julius D: Nature 389: 816-824, (1997)] and identified as a nonselective cation channel with six transmembrane domains that is structurally related to the TRP (transient receptor potential) channel family. Binding of capsaicin to VR1 allows sodium, calcium and possibly potassium ions to flow down their concentration gradients, causing initial depolarization and release of neuro-transmitters from the nerve terminals. VR1 can therefore be viewed as a molecular integrator of chemical and physical stimuli that elicit neuronal signals in a pathological conditions or diseases.
- There are abundant of direct or indirect evidence that shows the relation between VR1 activity and diseases such as pain, ischaemia, and inflammatory (e.g., WO 99/00115 and 00/50387). Further, it has been demonstrated that VR1 transduce reflex signals that are involved in the overactive bladder of patients who have damaged or abnormal spinal reflex pathways [De Groat W C: A neurologic basis for the overactive bladder. Urology 50 (6A Suppl): 36-52, 1997]. Desensitisation of the afferent nerves by depleting neurotransmitters using VR1 agonists such as capsaicin has been shown to give promising results in the treatment of bladder dysfunction associated with spinal cord injury and multiple sclerosis [(Maggi C A: Therapeutic potential of capsaicin-like molecules—studies in animals and humans. Life Sciences 51: 1777-1781, 1992) and (DeRidder D; Chandiramani V; Dasgupta P; VanPoppel H; Baert L; Fowler C J: Intravesical capsaicin as a treatment for refractory detrusor hyperreflexia: A dual center study with long-term followup. J. Urol. 158: 2087-2092, 1997)].
- It is anticipated that antagonism of the VR1 receptor would lead to the blockage of neurotransmitter release, resulting in prophylaxis and treatment of the condition and diseases associated with VR1 activity.
- It is therefore expected that antagonists of the VR1 receptor can be used for prophylaxis and treatment of the condition and diseases including chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, inflammatory disorders, urinary incontinence (UI) such as urge urinary incontinence (UUI), and/or overactive bladder.
- UI is the involuntary loss of urine. UUI is one of the most common types of UI together with stress urinary incontinence (SUI) which is usually caused by a defect in the urethral closure mechanism. UI is often associated with neurological disorders or diseases causing neuronal damages such as dementia, Parkinson's disease, multiple sclerosis, stroke and diabetes, although it also occurs in individuals with no such disorders. One of the usual causes of UUI is overactive bladder (OAB) which is a medical condition referring to the symptoms of frequency and urgency derived from abnormal contractions and instability of the detrusor muscle.
- There are several medications for urinary incontinence on the market today mainly to help treating UUI. Therapy for OAB is focused on drugs that affect peripheral neural control mechanisms, or those that act directly on bladder detrusor smooth muscle contraction, with a major emphasis on development of anticholinergic agents. These agents can inhibit the parasympathetic nerves which control bladder voiding or can exert a direct spasmolytic effect on the detrusor muscle of the bladder. This results in a decrease in intravesicular pressure, an increase in capacity and a reduction in the frequency of bladder contraction. Orally active anticholinergic drugs such as propantheline (ProBanthine), tolterodine tartrate (Detrol) and oxybutynin (Ditropan) are the most commonly prescribed drugs. However, their most serious drawbacks are unacceptable side effects such as dry mouth, abnormal visions, constipation, and central nervous system disturbances. These side effects lead to poor compliance. Dry mouth symptoms alone are responsible for a 70% non-compliance rate with oxybutynin. The inadequacies of present therapies highlight the need for novel, efficacious, safe, orally available drugs that have fewer side effects.
- WO 00/50387 discloses the compounds having a vanilloid agonist activity represented by the general formula:
- wherein;
- XP is an oxygen or sulfur atom;
- AP is —NHCH2— or —CH2—;
- Ra is a substituted or unsubstituted C1-4 alkyl group, or Ra1CO—;
- wherein
-
- Ra1 is an alkyl group having 1 to 18 carbon atoms, an alkenyl group having 2 to 18 carbon atoms, or substituted or unsubstituted aryl group having 6 to 10 carbon atoms;
- Rb is a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, a haloalkyl group having 1 to 6 carbon atoms or a halogen atom,
- RC is a hydrogen atom, an alkyl group having 1 to 4 carbon atom, an aminoalkyl, a diacid monoester or α-alkyl acid; and
the asteric mark * indicates a chiral carbon atom, and their pharmaceutically acceptable salts. - WO 2000/61581 discloses amine derivatives represented by the general formula:
- wherein
(R′, R″) represent (F, F), (CF3, H), or (iPr, iPr)
as useful agents for diabetes, hyperlipemia, arteriosclerosis and cancer. - WO 00/75106 discloses the compounds represented by the general formula:
- wherein
Z represents - in which
-
- R90 is hydrogen, C1-12 alkyl, C3-8 cycloakyl, or the like, and R91 is amino-C1-6 alkyl, aminocarbonyl-C1-6 alkyl, or hydroxyaminocarbonyl C1-6 alkyl; and
- R90 and R91 are independently selected from the group consisting of H, C1-6 alkyl, C1-6 alkylthio, C1-6 alkoxy, fluoro, chloro, bromo, iodo, and nitro;
as useful agents for treating MMP-mediated diseases in mammals.
- WO 00/55152 discloses the compounds represented by the general formula:
- wherein
Ar1 is heterocycle;
Ar2 is tetrahydronapthyl; - L and Q are defined in this specification;
as useful agents for treating inflammation, immune related disease, pain and diabetes. - However, none of these reference discloses simple tetrahydro-naphthalene derivatives having VR1 antagonistic activity.
- The development of a compound which has effective VR1 antagonistic activity and can be used for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, urge urinary incontinence, overactive bladder as well as pain, and/or inflammatory diseases such as asthma and COPD has been desired.
- This invention is to provide a tetrahydro-naphthalene derivatives of the formula (I), their tautomeric and stereoisomeric form, and salts thereof:
- wherein
-
- n represents an integer of 0 to 6;
- R1 represents hydrogen or C1-6 alkyl;
- R2 and R3 together with the nitrogen atom to which they are attached, form a 3-8 membered saturated heterocyclic ring optionally interrupted by one or two atoms selected from the group consisting of oxygen, sulfur and nitrogen,
- wherein
- said saturated heterocyclic ring is optionally having substituents selected from the group consisting of halogen, benzyl, hydroxy, carboxy, amino, oxo, aminocarbonyl, C1 alkoxycarbonyl, and C1-6 alkyl optionally substituted by hydroxy, carboxy, C1-6 alkoxy, or C1-6 alkoxycarbonyl, or
- R2 represents C2-6 alkenyl-C2-6 alkynyl, or C1-6 alkyl substituted by amino, hydroxy, C1-6 alkylamino, or di(C1-6 alkyl)amino;
- R3 represents hydrogen, C2-6 alkenyl, C2-6 alkynyl, or C1-6 alkyl optionally substituted by amino, hydroxy, C1-6 alkylamino, or di(C1-6 alkyl)amino; and
- R4 represents hydrogen halogen, C1-6 alkylthio, C1-6 alkyl optionally substituted by mono-, di-, or tri-halogen, or C1-6 alkoxy optionally substituted by mono-, di-, or tri-halogen.
- The tetrahydro-naphthalene derivatives of formula (I), their tautomeric and stereo-isomeric form, and salts thereof surprisingly show excellent VR1 antagonistic activity. They are, therefore suitable especially for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urinary incontinence, urge urinary incontinence and/or overactive bladder.
- The compounds of the present invention are also effective for treating or preventing a disease selected from the group consisting of chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration and/or stroke, as well as inflammatory diseases such as asthma and COPD since the diseases also relate to VR1 activity.
- The compounds of the present invention are also useful for the treatment and prophylaxis of neuropathic pain, which is a form of pain often associated with herpes zoster and post-herpetic neuralgia, painful diabetic neuropathy, neuropathic low back pain, posttraumatic and postoperative neuralgia, neuralgia due to nerve compression and other neuralgias, phantom pain, complex regional pain syndromes, infectious or parainfectious neuropathies like those associated with HIV infection, pain associated with central nervous system disorders like multiple sclerosis or Parkinson disease or spinal cord injury or traumatic brain injury, and post-stroke pain.
- Furthermore, the compounds of the present invention are useful for the treatment of musculoskeletal pain, forms of pain often associated with osteoarthritis or rheumatoid arthritis or other forms of arthritis, and back pain.
- In addition, the compounds of the present invention are useful for the treatment of pain associated with cancer, including visceral or neuropathic pain associated with cancer or cancer treatment.
- The compounds of the present invention are furthermore useful for the treatment of visceral pain, e.g. pain associated with obstruction of hollow viscus like gallstone colik, pain associated with irritable bowel syndrome, pelvic pain, vulvodynia, orchialgia or prostatodynia, pain associated with inflammatory lesions of joints, skin, muscles or nerves, and orofascial pain and headache, e.g. migraine or tension-type headache.
- In another embodiment, the tetrahydro-napththalene derivatives of formula (I) are those wherein;
-
- n represents an integer of 0 or 1;
- R1 represents hydrogen;
- R2 and R3 together with the nitrogen atom to which they are attached, form a 5-7 membered saturated heterocyclic ring optionally interrupted by one or two atoms selected from the group consisting of oxygen, and nitrogen,
- wherein
- said saturated heterocyclic ring is optionally having substituents selected from the group consisting of benzyl, hydroxy, carboxy, oxo, aminocarbonyl, C1-6 alkoxycarbonyl, and C1-6 alkyl optionally substituted by hydroxy, C1-6 alkoxy, or C1-6 alkoxycarbonyl, or
- R1 represents C1-6 alkyl substituted by hydroxy, amino, C1-6 alkylamino, or di(C1-6 alkyl)amino;
- R3 represents hydrogen, C1-6 alkyl optionally substituted by hydroxy, amino, C1-6 alkylamino, or di(C1-6 alkyl)amino; and
- R4 represents hydrogen halogen, C1-6 alkyl optionally substituted by mono-, di-, or tri-halogen, or C1-6 alkoxy optionally substituted by mono-, di-, or tri-halogen.
- Yet another embodiment of formula (I) can be those wherein:
-
- n represents an integer of 0 or 1;
- R1 represents hydrogen;
- R2 and R3 together with the nitrogen atom to which they are attached, form a pyrrolidinyl optionally substituted by oxo, piperidino optionally substituted by hydroxy, carboxy, aminocarbonyl, C1-6 alkoxycarbonyl, or C1-6 alkyl optionally substituted by hydroxy, piperazinyl optionally substituted by benzyl, homopiperidino, or morpholinyl, or
- R2 represents C1-6 alkyl substituted by hydroxy, or di(C1-6 alkyl)amino;
- R3 represents hydrogen, or C1-6 alkyl; and
- R4 represents hydrogen, fluoro, chloro, bromo, C1-6 alkyl optionally substituted by mono-, di-, or tri-halogen, or C1-6 alkoxy.
- More preferably, said tetrahydro-naphthalene derivative of the formula (I) is selected from the group consisting of:
- N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N′-[3-piperidin-1-yl-4-(trifluoromethyl)benzyl]urea;
- N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N′-[4-pyrrolidin-1-yl-3-(trifluoromethyl)benzyl]urea;
- N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N′-[3-pyrrolidin-1-yl-4-(trifluoromethyl)benzyl]urea;
- N-[4-azepan-1-yl-3-(trifluoromethyl)benzyl]-N′-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;
- N-[3-azepan-1-yl-4(trifluoromethyl)benzyl]-N′-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;
- N-(3-bromo-4-piperidin-1-ylbenzyl)-N′-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;
- N-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-N′-[3-pyrrolidin-1-yl-4-(trifluoromethyl)benzyl]urea;
- N-[(7S)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-N′-[3-pyrrolidin-1-yl-4-(trifluoromethyl)benzyl]urea;
- N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N′-[4-piperidin-1-yl-3-(trifluoromethyl)benzyl]urea;
- ethyl 1-[5-[({[(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)amino]carbonyl}amino)methyl]-2-(trifluoromethyl)phenyl]piperidine-4-carboxylate;
- N-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-N′-[3-morpholin-4-yl-4(trifluoromethyl)benzyl]urea
- Further, the present invention provides a medicament, which includes one of the compounds, described above and optionally pharmaceutically acceptable excipients.
- Alkyl per se and “alk” and “alkyl” in alkenyl, alkynyl, alkoxy, alkanoyl, alkylamino, alkylaminocarbonyl, alkylaminosulphonyl, alkylsulphonylamino, alkoxycarbonyl, alkoxycarbonylamino and alkanoylamino represent a linear or branched alkyl radical having generally 1 to 6, preferably 1 to 4 and particularly preferably 1 to 3 carbon atoms, representing illustratively and preferably methyl, ethyl, n-propyl, isopropyl, tert-butyl, n-pentyl and n-hexyl.
- Alkoxy illustratively and preferably represents methoxy, ethoxy, n-propoxy, isopropoxy, tert-butoxy, n-pentoxy and n-hexoxy.
- Alkylamino illustratively and preferably represents an alkylamino radical having one or two (independently selected) alkyl substituents, illustratively and preferably representing methylamino, ethylamino, n-propylamino, isopropylamino, tert-butylamino, n-pentylamino, n-hexyl-amino, N,N-dimethylamino, N,N-diethylamino, Nethyl-N-methylamino, N-methyl-N-n-propylamino, N-isopropyl-N-n-propylamino, N-t-butyl-N-methylamino, N-ethyl-N-n-pentylamino and N-n-hexyl-N-methylamino.
- Heterocycle and/or heterocyclic as used herein, designate a closed ring structure, in which one or more of the atoms in the ring is a heteroatom such as sulfur, nitrogen, oxygen, and the like. Suitable examples include, without limitation, pyrrolidinyl, piperidino, piperazinyl homopiperidino, morpholinyl, thiomorpholinyl, tetrahydrofuryl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, pyridyl pyrazinyl, pyrimidyl, pyridazinyl and the like.
- The compound of the formula (I) of the present invention can be, but not limited to be, prepared by combining various known methods. In some embodiments, one or more of the substituents, such as amino group, carboxyl group, and hydroxyl group of the compounds used as starting materials or intermediates are advantageously protected by a protecting group known to those skilled in the art. Examples of the protecting groups are described in “Protective Groups in Organic Synthesis (3rd Edition)” by Greene and Wuts, John Wiley and Sons, New York 1999.
- The compound of the formula (I) of the present invention can be, but not limited to be, prepared by the Method [A], [B], [C], [D], [E], [F], [G] or [H] below.
- The compound of the formula (I) (wherein n, R1, R2, R3, and R4 are the same as defined above) can be prepared by reacting the compound of the formula (II) (wherein R1 is the same as defined above) and the compound of the formula (III) (wherein L1 represents halogen atom such as chlorine, bromine, or iodine atom) and then adding the compound of the formula (IV) (wherein n, R2, R3, and R4 are the same as defined above) to the reaction mixture.
- The reaction may be carried out in a solvent including, for instance, halogenated hydrocarbons such as dichloromethane, chloroform and 1,2-dichloroethane; ethers such as diethyl ether, isopropyl ether, dioxane and tetrahydrofuran (THF) and 1,2-dimethoxyethane; aromatic hydrocarbons such as benzene, toluene and xylene; nitriles such as acetonitrile; amides such as N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMAC) and N-methylpyrrolidone (NMP); urea such as 1,3-dimethyl-2-imidazolidinone (DMI); sulfoxides such as dimethylsulfoxide (DMSO); and others. Optionally, two or more of the solvents selected from the listed above can be mixed and used.
- The reaction temperature can be optionally set depending on the compounds to be reacted. The reaction temperature is usually, but not limited to, about 20° C. to 50° C. The reaction may be conducted for, usually, 30 minutes to 10 hours and preferably 1 to 24 hours.
- The reaction can be advantageously carried out in the presence of a base including, for instance, organic amines such as pyridine, triethylamine and N,N-diisopropylethylamine, dimethylaniline, diethylaniline, 4-dimethylaminopyridine, and others.
- The compound (II) and (IV) are commercially available or can be prepared by the use of known techniques.
- The compound of the formula (I) (wherein n, R1, R2, R3, and R4 are the same as defined above) can be prepared by the reaction of the compound of the formula (II) (wherein R1 is the same as defined above) and the compound of the formula (V) (wherein n, R2, R3 and R4 are the same as defined above).
- The reaction may be carried out in a solvent including, for instance, halogenated hydrocarbons such as dichloromethane, chloroform and 1,2-dichloroethane; ethers such as diethyl ether, isopropyl ether, dioxane and tetrahydrofuran (THF) and 1,2-dimethoxyethane; aromatic hydrocarbons such as benzene, toluene and xylene; nitriles such as acetonitrile; amides such as N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMAC) and N-methylpyrrolidone NP); urea such as 1,3-dimethyl-2-imidazolidinone (DMI); sulfoxides such as dimethylsulfoxide (DMSO); and others. Optionally, two or more of the solvents selected from the listed above can be mixed and used.
- The reaction can be carried out in the presence of organic base such as pyridine or triethylamine.
- The reaction temperature can be optionally set-depending on the compounds to be reacted. The reaction temperature is usually, but not limited to, about room temperature to 100° C. The reaction may be conducted for, usually, 30 minutes to 48 hours and preferably 1 to 24 hours.
- The compound (V) can be prepared by the use of known techniques or are commercially available.
- The compound of the formula (I) (wherein n, R1, R2, R3, and R4 are the same as defined above) can be prepared by reacting the compound of the formula (II) (wherein R1 is the same as defined above) with phosgene, diphosgene, triphosgene, 1,1-carbonyldiimidazole (CDI), or 1,1′-carbonyldi(1,2,4-triazole)(CDT), and then adding the compound of the formula (I) (wherein n, R2, R3, and R4 are the same as defined above) to the reaction mixture.
- The reaction may be carried out in a solvent including, for instance, halogenated hydrocarbons such as dichloromethane, chloroform and 1,2-dichloroethane; ethers such as diethyl ether, isopropyl ether, dioxane and tetrahydrofuran (THF) and 1,2-dimethoxyethane; aromatic hydrocarbons such as benzene, toluene and xylene; nitrites such as acetonitrile; amides such as N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMAC) and N-methylpyrrolidone (NMP); urea such as 1,3-dimethyl-2-imidazolidinone (DMI; sulfoxides such as dimethylsulfoxide (DMSO); and others. Optionally, two or more of the solvents selected from the listed above can be mixed and used.
- The reaction temperature can be optionally set depending on the compounds to be reacted. The reaction temperature is usually, but not limited to, about 20° C. to 50° C.
- The reaction may be conducted for, usually, 30 minutes to 10 hours and preferably 1 to 24 hours.
- Phosgene, diphosgene, triphosgene, CDI, and CDT are commercially available.
- The compound of the formula (I) (wherein n, R1, R2, R3 and R4 are the same as defined above) can be prepared by reacting the compound of the formula (IV) (wherein n, R2, R3, and R4 are the same as defined above) with phosgene, diphosgene, triphosgene, 1,1-carbonyldiimidazole (CDI), or 1,1′-carbonyldi(1,2,4-triazole) (CDT) and then adding the compound of the formula (II) (wherein R1 is the same as defined above) to the reaction mixture.
- The reaction may be carried out in a solvent including, for instance, halogenated hydrocarbons such as dichloromethane, chloroform and 1,2-dichloroethane; ethers such as diethyl ether, isopropyl ether, dioxane and tetrahydrofuran (THF) and 1,2-dimethoxyethane; aromatic hydrocarbons such as benzene, toluene and xylene; nitriles such as acetonitrile; amides such as N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMAC) and N-methylpyrrolidone (NMP); urea such as 1,3-dimethyl-2-imidazolidinone (DMI); sulfoxides such as dimethylsulfoxide (DMSO); and others. Optionally, two or more of the solvents selected from the listed above can be mixed and used.
- The reaction temperature can be optionally set depending on the compounds to be reacted. The reaction temperature is usually, but not limited to, about 20° C. to 50° C. The reaction may be conducted for, usually, 30 minutes to 10 hours and preferably 1 to 24 hours.
- The compound of the formula (I) (wherein n, R1, R2, R3 and R4 are the same as defined above) can be prepared by reacting the compound of the formula (IV) (Wherein n, R2, R3, and R4 are the same as defined above) and the compound of the formula (III) (wherein L1 is the same as defined above), and then adding the compound of the formula (II) (wherein R1 is the same as defined above) to the reaction mixture.
- The reaction may be carried out in a solvent including, for instance, halogenated hydrocarbons such as dichloromethane, chloroform and 1,2-dichloroethane; ethers such as diethyl ether, isopropyl ether, dioxane and tetrahydrofuran (THF) and 1,2-dimethoxyethane; aromatic hydrocarbons such as benzene, toluene and xylene; nitrites such as acetonitrile; amides such as N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMAC) and N-methylpyrrolidone (NMP); urea such as 1,3-dimethyl-2-imidazolidinone (DM); sulfoxides such as dimethylsulfoxide (DMSO); and others. Optionally, two or more of the solvents selected from the listed above can be mixed and used.
- The reaction temperature can be optionally set depending on the compounds to be reacted. The reaction temperature is usually, but not limited to, about 20° C. to 50° C. The reaction may be conducted for, usually, 30 minutes to 10 hours and preferably 1 to 24 hours.
- The reaction can be advantageously carried out in the presence of a base including, for instance, organic amines such as pyridine, triethylamine and N,N-diisopropylethylamine, dimethylaniline, diethylamine, 4-dimethylaminopyridine, and others.
- The compound of the formula (I) (wherein n, R1, R2, R3 and R4 are the same as defined above) can be prepared by the following procedures in three steps;
- In the Step F-1, the compound of the formula (VII) (wherein n, R1, R2, R3 and R4 are the same as defined above) can be prepared by reacting the compound of the formula (VI) (wherein R1 is the same as defined above) with the compound of the formula (V) (wherein n, R2, R3 and R4 are the same as defined above) in a similar manner described in Method B for the preparation of the compound of the formula (I).
- In the Step F-2, the compound of the formula (VIII) (wherein n, R1, R2, R3, and R4 are the same as defined above) can be prepared by reacting the compound of the formula (VII) (wherein n, R1, R2, R3, and R4 are the same as defined above) with an acid such as hydrochloric acid.
- The reaction may be carried out in a solvent including, for instance, halogenated hydrocarbons such as dichloromethane, chloroform and 1,2-dichloroethane; ethers such as diethyl ether, isopropyl ether, dioxane and tetrahydrofuran (THF) and 1,2-dimethoxyethane; alcohols such as methanol, ethanol; water and others. Optionally, two or more of the solvents selected from the listed above can be mixed and used.
- The reaction temperature can be optionally set depending on the compounds to be reacted. The reaction temperature is usually, but not limited to, about 20° C. to 10° C. The reaction may be conducted for, usually, 30 minutes to 10 hours and preferably 1 to 24 hours.
- In the Step F-3, the compound of the formula (I) (wherein n, R1, R2, R3 and R4 are the same as defined above) can be prepared by reacting the compound of the formula (VIII) (wherein n, R1, R2, R3 and R4 are the same as defined above) with reducing agent such as sodium borohydride or lithium aluminum hydride.
- The reaction may be carried out in a solvent including, for instance, ethers such as diethyl ether, isopropyl ether, dioxane and tetrahydrofuran (THF) and 1,2-dimethoxyethane; alcohols such as methanol, ethanol, isopropanol, and others. Optionally, two or more of the solvents selected from the listed above can be mixed and used.
- The reaction temperature can be optionally set depending on the compounds to be reacted. The reaction temperature is usually, but not limited to, about 20° C. to 50° C. The reaction may be conducted for, usually, 30 minutes to 10 hours and preferably 1 to 24 hours.
- The compound (VI) is commercially available or can be prepared by the use of known techniques.
- The compound of the formula (I) (wherein n, R1, R2, R3 and R4 are the same as defined above) can be obtained by the reaction of the compound of the formula (X) (wherein n, R1, R2, R3, R4 and L are the same as defined above) with the compound of the formula (IX) (wherein R2 and R3 are the same as defined above).
- The reaction may be carried out in a solvent including, for instance, ethers such as diethyl ether, isopropyl ether, dioxane and tetrahydrofuran (THF) and 1,2-dimethoxyethane; aromatic hydrocarbons such as benzene, toluene and xylene; amides such as N,N-dimethylformamide (DMF), N,N-dimethylacetamide and N-methylpyrrolidone; sulfoxides such as dimethylsulfoxide (DMSO); alcohols such as methanol, ethanol, 1-propanol, isopropanol and tert-butanol; water and others. Optionally, two or more of the solvents selected from the listed above can be mixed and used.
- The reaction can be advantageously carried out in the presence of an catalyst such as palladium catalysts and others.
- The reaction temperature can be optionally set depending on the compounds to be reacted. The reaction temperature is usually, but not limited to, about 20° C. to 120° C. The reaction may be conducted for, usually, 30 minutes to 60 hours and preferably 1 to 48 hours.
- The compound (X) can be prepared in a similar manner as described in Method [A], [B], [C], [D], [E], or [F] for the preparation of the compound of the formula (I) using a compound
- (wherein n, L and R4 are the same as defined above) instead of the compound m or (V).
- The stereoisomeric form of the compound (I), R form (I-i) (wherein n, R1, R2, R3, and R4 are the same as defined above) can be prepared by the reaction of the compound of the formula (II-i) (wherein R1 is the same as defined above) with the compound of the formula (V) (wherein n, R2, R3, and R4 are the same as defined above) in a similar manner described in Method. B for the preparation of the compound of the formula (I).
- The stereoisomeric form of the compound (I), S form (I-ii) (wherein n, R1, R2, R3, and R4 are the same as defined above) can be prepared by the reaction of the compound of (II-ii) (wherein R1 is the same as defined above) with the compound of the formula (V) (wherein n, R1, R2, R3, and R4 are the same as defined above) in a similar manner described in Method B for the preparation of the compound of the formula (I).
- The compound (II-i) or (II-ii) can be prepared by the use of known techniques.
- When the compound shown by the formula (I) or a salt thereof has an asymmetric carbon in the structure, their optically active compounds and racemic mixtures are also included in the scope of the present invention.
- Typical salts of the compound shown by the formula (I) include salts prepared by reaction of the compounds of the present invention with a mineral or organic acid, or an organic or inorganic base. Such salts are known as acid addition and base addition salts, respectively.
- Acids to form acid addition salts include inorganic acids such as, without limitation, sulfuric acid, phosphoric acid, hydrochloric acid, hydrobromic acid, hydriodic acid and the like, and organic acids, such as, without limitation, p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like.
- Base addition salts include those derived from inorganic bases, such as, without limitation, ammonium hydroxide, alkaline metal hydroxide, alkaline earth metal hydroxides, carbonates, bicarbonates, and the like, and organic bases, such as, without limitation, ethanolamine, triethylamine, tris(hydroxymethyl)aminomethane, and the like. Examples of inorganic bases include sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate, calcium hydroxide, calcium carbonate, and the like.
- The compound of the present invention or a salt thereof, depending on its substituents, may be modified to form lower alkylesters or known other esters; and/or hydrates or other solvates. Those esters, hydrates, and solvates are included in the scope of the present invention.
- The compound of the present invention may be administered in oral forms, such as, without limitation normal and enteric coated tablets, capsules, pills, powders, granules, elixirs, tinctures, solution, suspensions, syrups, solid and liquid aerosols and emulsions. They may also be administered in parenteral forms, such as, without limitation, intravenous, intraperitoneal, subcutaneous, intramuscular, and the like forms, well-known to those of ordinary skill in the pharmaceutical arts. The compounds of the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or via transdermal routes, using trans-dermal delivery systems well-known to those of ordinary skilled in the art.
- The dosage regimen with the use of the compounds of the present invention is selected by one of ordinary skill in the arts, in view of a variety of factors, including, without limitation, age, weight, sex, and medical condition of the recipient, the severity of the condition to be treated, the route of administration, the level of metabolic and excretory function of the recipient, the dosage form employed, the particular compound and salt thereof employed
- The compounds of the present invention are preferably formulated prior to administration together with one or more pharmaceutically-acceptable excipients. Excipients are inert substances such as, without limitation carriers, diluents, flavoring agents, sweeteners, lubricants, solubilizers, suspending agents, binders, tablet disintegrating agents and encapsulating material.
- Yet another embodiment of the present invention is pharmaceutical formulation comprising a compound of the invention and one or more pharmaceutically-acceptable excipients that are compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. Pharmaceutical formulations of the invention are prepared by combining a therapeutically effective amount of the compounds of the invention together with one or more pharmaceutically-acceptable excipients therefore. In making the compositions of the present invention, the active ingredient may be mixed with a diluent, or enclosed within a carrier, which may be in the form of a capsule, sachet, paper, or other container. The carrier may serve as a diluent, which may be solid, semi-solid, or liquid material which acts as a vehicle, or can be in the form of tablets, pills powders, lozenges, elixirs, suspensions, emulsions, solutions, syrups, aerosols, ointments, containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders.
- For oral administration, the active ingredient may be combined with an oral, and non-toxic, pharmaceutically-acceptable carrier, such as, without limitation, lactose, starch, sucrose, glucose, sodium carbonate, mannitol, sorbitol, calcium carbonate, calcium phosphate, calcium sulfate, methyl cellulose, and the like; together with, optionally, disintegrating agents, such as, without limitation, maize, starch, methyl cellulose, agar bentonite, xanthan gum, alginic acid, and the like; and optionally, binding agents, for example, without limitation, gelatin, natural sugars, beta-lactose, corn sweeteners, natural and synthetic gums, acacia, tragacanth, sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes, and the like; and, optionally, lubricating agents, for example, without limitation, magnesium stearate, sodium stearate, stearic acid, sodium oleate, sodium benzoate, sodium acetate, sodium chloride, talc, and the like.
- In powder forms, the carrier may be a finely divided solid which is in admixture with the finely divided active ingredient. The active ingredient may be mixed with a carrier having binding properties in suitable proportions and compacted in the shape and size desired to produce tablets. The powders and tablets preferably contain from about 1 to about 99 weight percent of the active ingredient which is the novel composition of the present invention. Suitable solid carriers are magnesium carboxymethyl cellulose, low melting waxes, and cocoa butter.
- Sterile liquid formulations include suspensions, emulsions, syrups and elixirs. The active ingredient can be dissolved or suspended in a pharmaceutically acceptable carriers, such as sterile water, sterile organic solvent, or a mixture of both sterile water and sterile organic solvent.
- The active ingredient can also be dissolved in a suitable organic solvent, for example, aqueous propylene glycol. Other compositions can be made by dispersing the finely divided active ingredient in aqueous starch or sodium carboxymethyl cellulose solution or in a suitable oil.
- The formulation may be in unit dosage form, which is a physically discrete unit containing a unit dose, suitable for administration in human or other mammals. A unit dosage form can be a capsule or tablets, or a number of capsules or tablets. A “unit dose” is a predetermined quantity of the active compound of the present invention, calculated to produce the desired therapeutic effect, in association with one or more excipients. The quantity of active ingredient in a unit dose may be varied or adjusted from about 0.1 to about 1000 milligrams or more according to the particular treatment involved.
- Typical oral dosages of the present invention, when used for the indicated effects, will range from about 0.01 mg/kg/day to about 100 mg/kg/day, preferably from 0.1 mg/kg/day to 30 mg/kg/day, and most preferably from about 0.5 mg/kg/day to about 10 mg/kg/day. In the case of parenteral administration, it has generally proven advantageous to administer quantities of about 0.001 to 100 mg/kg/day, preferably from 0.01 mg/kg/day to 1 mg/kg/day. The compounds of the present invention may be administered in a single daily dose, or the total daily dose may be administered in divided doses, two, three, or more times per day. Where delivery is via transdermal forms, of course, administration is continuous.
- The present invention will be described as a form of examples, but they should by no means be construed as defining the metes and bounds of the present invention.
- In the examples below, all quantitative data, if not stated otherwise, relate to percentages by weight.
- Mass spectra were obtained using electrospray (ES) ionation techniques (micromass Platform LC). Melting points are uncorrected. Liquid Chromatography—Mass spectroscopy (LC-MS) data were recorded on a Micromass Platform LC with Shimadzu Phenomenex ODS column (4.6 mmφ×30 mm) flushing a mixture of acetonitrile-water (9:1 to 1:9) at 1 ml/min of the flow rate. TLC was performed on a precoated silica gel plate (Merck silica gel 60 F-254). Silica gel (WAKO-gel C-200 (75-150 μm)) was used for all column chromatography separations. All chemicals were reagent grade and were purchased from Sigma-Aldrich, Wako pure chemical industries, Ltd., Great Britain, Tokyo kasei kogyo Co., Ltd., Nacalai tesque, Inc., Watanabe Chemical Ind. Ltd., Maybridge plc, Lancaster Synthesis Ltd., Merck KgaA, Germany, Kanto Chemical Co., Ltd.
- 1H NMR spectra were recorded using either Bruker DRX-300 (300 MHz for 1H) spectrometer or Brucker 500 Ultrashieled™ (500 MHz for 1H). Chemical shifts are reported in parts per million (ppm) with tetramethylsilane (TMS) as an internal standard at zero ppm. Coupling constant (J) are given in hertz and the abbreviations s, d, t, q, m, and br refer to singlet, doblet, triplet, quartet, multiplet, and broad, respectively. The mass determinations were carried out by MAT95 (Finnigan MAT).
- All starting materials are commercially available or can be prepared using methods cited in the literature.
- The effect of the present compounds was examined by the following assays and pharmacological tests.
- Human vanilloid receptor (hVR1) cDNA was cloned from libraries of axotomized dorsal root ganglia (WO 00/29577). The cloned hVR1 cDNA was constructed with pcDNA3 vector and transfected into a CHOluc9aeq cell line. The cell line contains aequorin and CRE-luciferase reporter genes as read-out signals. The transfectants were cloned by limiting dilution in selection medium (DMEM/F12 medium (Gibco BRL) supplemented with 10% FCS, 1.4 mM Sodium pyravate, 20 mM HEPES, 0.15% Sodium bicarbonate, 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM glutamine, non-essential amino acids and 2 mg/ml G418). Ca2+ influx was examined in the capsaicin-stimulated clones. A high responder clone was selected and used for further experiments in the project. The human VR1-CHOluc9aeq cells were maintained in the selection medium and passaged every 3-4 days at 1-2.5×105 cells/flask (75 mm2).
- Human VR1-CHOluc9aeq cells were suspended in a culture medium which is the same as the selection medium except for G418 and seeded at a density of 1,000 cells per well into 384-well plates (black walled clear-base/Nalge Nunc International). Following the culture for 48 hrs the medium was changed to 2 μM Fluo-3 AM (Molecular Probes) and 0.02% Puronic F-127 in assay buffer (Hank's balanced salt solution (HBSS), 17 mM HEPES (pH7.4), 1 mM Probenecid, 0.1% BSA) and the cells were incubated for 60 min at 25° C. After washing twice with assay buffer the cells were incubated with a test compound or vehicle for 20 min at 25° C. Mobilization of cytoplasmic Ca2+ was measured by FDSS-3000 (λex=88nm, λem=540 nm/Hamamatsu Photonics) for 60 sec after the stimulation with 10 nM capsaicin. Integral R was calculated and compared with controls.
- New born Wister rats (5-11 days) were sacrificed and dorsal root ganglia (DRG) was removed. DRG was incubated with 0.1% trypsin (Gibco BRL) in PBS(−) (Gibco BRL) for 30 min at 37° C., then a half volume of fetal calf serum (FCS) was added and the cells were spun down. The DRG neuron cells were resuspended in Ham F12/5% FCS/5% horse serum (Gibco, BRL) and dispersed by repeated pipetting and passing through 70 m mesh (Falcon). The culture plate was incubated for 3 hours at 37° C. to remove contaminating Schwann cells. Non-adherent cells were recovered and further cultured in laminin-coated 384 well plates (Nunc) at 1×104 cells/50 μl/well for 2 days in the presence of 50 ng/ml recombinant rat NGF (Sigma) and 50 μM 5-fluorodeoxyuridine (Sigma).
- DRG neuron cells were washed twice with HBSS supplemented with 17 mM HEPES (pH 7.4) and 0.1% BSA. After incubating with 2 μM fluo-3AM (Molecular Probe), 0.02% PF127 (Gibco BRL) and 1 mM probenecid (Sigma) for 40 min at 37° C., cells were washed 3 times. The cells were incubated with VR1 antagonists or vehicle (dimethylsulphoxide) and then with 1 μM capsaicin in FDSS-6000 (λex=480 nm, λem=520 nm/Hamamatsu Photonics). The fluorescence changes at 480 nm were monitored for 2.5% min. Integral R was calculated and compared with controls.
- Male Wistar rats (10 week old) were anesthetized with ether and sacrificed by dislocating the necks. The whole urinary bladder was excised and placed in oxygenated Modified Krebs-Henseleit solution (pH 7.4) of the following composition (112 mM NaCl, 5.9 mM KCl, 1.2 mM MgCl2, 1.2 mM NaH2PO4, 2 mM CaCl2, 2.5 mM NaHCO3, 12 mM glucose). Contractile responses of the urinary bladder were studied as described previously [Maggi C A et al: Br. J. Pharmacol. 108: 801-805, 1993]. Isometric tension was recorded under a load of 1 g using longitudinal strips of rat detrusor muscle. Bladder strips were equilibrated for 60 min before each stimulation. Contractile response to 80 mM KCl was determined at 15 min intervals until reproducible responses were obtained. The response to KCl was used as an internal standard to evaluate the maximal response to capsaicin. The effects of the compounds were investigated by incubating the strips with compounds for 30 min prior to the stimulation with 1 μM capsaicin (vehicle: 80% saline, 10% EtOH, and 10% Tween 80). One of the preparations made from the same animal was served as a control while the others were used for evaluating compounds. Ratio of each capsaicin-induced contraction to the internal standard (i.e. KCl-induced contraction) was calculated and the effects of the test compounds on the capsaicin-induced contraction were evaluated.
- Human P2X1-transfected CHOluc9aeq cell line was established and maintained in Dulbecco's modified Eagle's medium (DMEM/F12) supplemented with 7.5% FCS, 0.20 mM HEPES-KOH (pH 7.4), 1.4 mM sodium pyruvate, 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM glutamine (Gibco BRL) and 0.5 Units/ml apyrase (grade I, Sigma). The suspended cells were seeded in each well of 384-well optical bottom black plates (Nalge Nunc International) at 3×103/50 μl/well. The cells were cultured for following 48 hrs to adhere to the plates.
- P2X1 receptor agonist-mediated increases in cytosolic Ca2+ levels were measured using a fluorescent Ca2+ chelating dye, Fluo-3 AM (Molecular Probes). The plate-attached cells were washed twice with washing buffer (HBSS, 17 mM HEPES-KOH (pH 7.4), 0.1% BSA and 0.5 units/ml apyrase), and incubated in 40 μl of loading buffer (1 μM Fluo-3 AM, 1 mM probenecid, 1 μM cyclosporin A, 0.01% pluronic (Molecular Probes) in washing buffer) for 1 hour in a dark place. The plates were washed twice with 40 μl washing buffer and 35 μl of washing buffer were added in each well with 5 μl of test compounds or 2′,3′-o-(2,4,6-trinitrophenyl) adenosine 5′-triphosphate (Molecular Probes) as a reference. After further incubation for 10 minutes in dark 200 nM α,β-methylene ATP agonist was added to initiate the Ca2+ mobilization. Fluorescence intensity was measured by FDSS-6000 (λex=410 nm, λem=510 nm/Hamamatsu Photonics) at 250 msec intervals. Integral ratios were calculated from the data and compared with that of a control.
- Female Sprague-Dawley rats (200˜250 g/Charles River Japan) were used.
- Rats were anesthetized by intraperitoneal administration of urethane (Sigma) at 1.2 g/kg. The abdomen was opened through a midline incision, and a polyethylene catheter (BECTON DICKINSON, PE50) was implanted into the bladder through the dome. In parallel the inguinal region was incised, and a polyethylene catheter (Hibiki, size 5) filled with 2 IU/ml of heparin (Novo Heparin, Aventis Pharma) in saline (Otsuka) was inserted into a common iliac artery.
- The bladder catheter was connected via T-tube to a pressure transducer (Viggo-Spectramed Pte Ltd, DT-XXAD) and a microinjection pump (TERUMO). Saline was infused at room temperature into the bladder at a rate of 2.4 ml/hr. Intravesical pressure was recorded continuously on a chart pen recorder (Yokogawa). At least three reproducible micturition cycles, corresponding to a 20-minute period, were recorded before a test compound administration and used as baseline values.
- (4) Administration of Test Compounds and Stimulation of Bladder with Capsaicin
- The saline infusion was stopped before administrating compounds. A testing compound dissolved in the mixture of ethanol, Tween 80 (ICN Biomedicals Inc.) and saline (1:1:8, v/v/v) was administered intraarterially at 10 mg/kg. 2 min after the administration of the compound 10 μg of capsaicin (Nacalai Tesque) dissolved in ethanol was administered intraarterially.
- Relative increases in the capsaicin-induced intravesical pressure were analyzed from the cystometry data. The capsaicin-induced bladder pressures were compared with the maximum bladder pressure during micturition without the capsaicin stimulation. The testing compounds-mediated inhibition of the increased bladder pressures was evaluated using Student's t-test. A probability level less than 5% was accepted as significant difference.
- Female Sprague-Dawley rats (180˜250 g/Charles River Japan) were used. Cyclophosphamide (CYP) dissolved in saline was administered intra-peritoneally at 150 mg/kg 48 hours before experiment.
- Rats were anesthetized by intraperitoneal administration of urethane (Sigma) at 1.25 g/kg. The abdomen was opened through a midline incision, and a polyethylene catheter (BECTON DICKINSON, PE50) was implanted into the bladder through the dome. In parallel, the inguinal region was incised, and a polyethylene catheter (BECTON DICKINSON, PE50) filled with saline (Otsuka) was inserted into a femoral vein. After the bladder was emptied, the rats were left for 1 hour for recovery from the operation.
- The bladder catheter was connected via T-tube to a pressure transducer (Viggo-Spectramed Pte Ltd, DT-XXAD) and a microinjection pump (TERUMO). Saline was infused at room temperature into the bladder at a rate of 3.6 ml/hr for 20 min. Intravesical pressure was recorded continuously on a chart pen recorder (Yokogawa). At least three reproducible micturition cycles, corresponding to a 20-minute-period, were recorded before a test compound administration.
- A testing compound dissolved in the mixture of ethanol, Tween 80 (ICN Biomedicals Inc.) and saline (1:1:8, v/v/v) was administered intravenously at 0.05 mg/kg, 0.5 mg/kg or 5 mg/kg. 3 min after the administration of the compound, saline (Nacalai Tesque) was infused at room temperature into the bladder at a rate of 3.6 ml/hr.
- The cystometry parameters were analyzed as described previously [Lecci A et al: Eur. J. Pharmacol. 259: 129-135, 1994]. The micturition frequency calculated from micturition interval and the bladder capacity calculated from a volume of infused saline until the first micturition were analyzed from the cystometry data. The testing compounds—mediated inhibition of the frequency and the testing compounds—mediated increase of bladder capacity were evaluated using unpaired Student's t-test. A probability levels less than 5% was accepted as significant difference. Data were analyzed as the mean±SEM from 4-7 rats.
- Acute pain is measured on a hot plate mainly in rats. Two variants of hot plate testing are used: In the classical variant animals are put on a hot surface (52 to 56° C.) and the latency time is measured until the animals show nociceptive behavior, such as stepping or foot licking. The other variant is an increasing temperature hot plate where the experimental animals are put on a surface of neutral temperature. Subsequently this surface is slowly but constantly heated until the animals begin to lick a hind paw. The temperature which is reached when hind paw licking begins is a measure for pain threshold.
- Compounds are tested against a vehicle treated control group. Substance application is performed at different time points via different application routes (i.v., i.p., p.o., i.t., i.c.v., S.C., intradermal, transdermal) prior to pain testing.
- Persistent pain is measured with the formalin or capsaicin test, mainly in rats. A solution of 1 to 5% formalin or 10 to 100 μg capsaicin is injected into one hind paw of the experimental animal. After formalin or capsaicin application the animals show nociceptive reactions like flinching, licking and biting of the affected paw. The number of nociceptive reactions within a time frame of up to 90 minutes is a measure for intensity of pain.
- Compounds are tested against a vehicle treated control group. Substance application is performed at different time points via different application routes (i.v., i.p., p.o., i.t., i.c.v., s.c., intradermal, transdermal) prior to formalin or capsaicin administration.
- Neuropathic pain is induced by different variants of unilateral sciatic nerve injury mainly in rats. The operation is performed under anesthesia. The first variant of sciatic nerve injury is produced by placing loosely constrictive ligatures around the common sciatic nerve (Bennett and Xie, Pain 33 (1988): 87-107). The second variant is the tight ligation of about the half of the diameter of the common sciatic nerve (Seltzer et al., Pain 43 (1990): 205-218). In the next variant, a group of models is used in which tight ligations or transections are made of either the L5 and L6 spinal nerves, or the L5 spinal nerve only (KIM S H; CHUNG J M, AN EXPERIMENTAL-MODEL FOR PERIPHERAL NEUROPATHY PRODUCED BY SEGMENTAL SPINAL NERVE LIGATION IN THE RA, PAIN 50 (3) (1992): 355-363). The fourth variant involves an axotomy of two of the three terminal branches of the sciatic nerve (tibial and common peroneal nerves) leaving the remaining sural nerve intact whereas the last variant comprises the axotomy of only the tibial branch leaving the sural and common nerves uninjured. Control animals are treated with a sham operation.
- Postoperatively, the nerve injured animals develop a chronic mechanical allodynia, cold allodynioa, as well as a thermal hyperalgesia. Mechanical allodynia is measured by means of a pressure transducer (electronic von Frey Anesthesiometer, IITC Inc.—Life Science Instruments, Woodland Hills, SA, USA; Electronic von Frey System, Somedic Sales AB, Hörby, Sweden). Thermal hyperalgesia is measured by means of a radiant heat source (Plantar Test, Ugo Basile, Comerio, Italy), or by means of a cold plate of 5 to 10° C. where the nocifensive reactions of the affected hind paw are counted as a measure of pain intensity. A further test for cold induced pain is the counting of nocifensive reactions, or duration of nocifensive responses after plantar administration of acetone to the affected hind limb. Chronic pain in general is assessed by registering the circadanian rhytms in activity (Surjo and Arndt, Universität zu Köln, Cologne, Germany), and by scoring differences in gait (foot print patterns; FOOTPRINTS program, Klapdor et al., 1997. A low cost method to analyse footprint patterns. J. Neurosci. Methods 75, 49-54).
- Compounds are tested against sham operated and vehicle treated control groups. Substance application is performed at different time points via different application routes (i.v., i.p., p.o., i.t., i.c.v., S.C., intradermal, transdermal) prior to pain testing.
- Inflammatory pain is induced mainly in rats by injection of 0.75 mg carrageenan or complete Freund's adjuvant into one hind paw. The animals develop an edema with mechanical allodynia as well as thermal hyperalgesia. Mechanical allodynia is measured by means of a pressure transducer (electronic von Frey Anesthesiometer, IITC Inc.—Life Science Instruments, Woodland Hills, SA, USA). Thermal hyperalgesia is measured by means of a radiant heat source (Plantar Test, Ugo Basile, Comerio, Italy, Paw thermal stimulator, G. Ozaki, University of California, USA). For edema measurement two methods are being used. In the first method, the animals are sacrificed and the affected hindpaws sectioned and weighed. The second method comprises differences in paw volume by measuring water displacement in a plethysmometer (Ugo Basile, Comerio, Italy).
- Compounds are tested against uninflamed as well as vehicle treated control groups. Substance application is performed at different time points via different application routes (i.v., i.p., p.o., i.t., i.c.v., s.c., intradermal, transdermal) prior to pain testing.
- Rats treated with a single intraperitoneal injection of 50 to 80 mg/kg streptozotocin develop a profound hyperglycemia and mechanical allodynia within 1 to 3 weeks. Mechanical allodynia is measured by means of a pressure transducer (electronic von Frey Anesthesiometer, IITC Inc.—Life Science Instruments, Woodland Hills, SA, USA).
- Compounds are tested against diabetic and non-diabetic vehicle treated control groups. Substance application is performed at different time points via different application routes (i.v., i.p., p.o., i.t., i.c.v., s.c., intradermal, transdermal) prior to pain testing.
- Results of IC 50 of capsaicin-induced Ca2+ influx in the human VR1-transfected CHO cell line are shown in Examples and tables of the Examples below. The data corresponds to the compounds as yielded by solid phase synthesis and thus to levels of purity of about 40 to 90%. For practical reasons, the compounds are grouped in four classes of activity as follows:
-
IC 50 =A(< or =)0.1 μM<B(< or =)0.5 μM<C(< or =)1 μM<D - The compounds of the present invention also show excellent selectivity, and strong activity in other assays 2-5 described above.
- Z used in Melting point in the following section indicates decomposition.
-
- To a stirred solution of 8-amino-2-naphthol (50.0 g, 314 mmol) in tetrahydrofuran (1000 mL) was added di-t-butyldicarbonate (68.6 g, 314 mmol). The mixture was stirred at 70° C. for 18 hours. After the mixture was cooled to room temperature, solvent was removed under reduced pressure. To the residue was added ethylacetate, and washed with saturated aqueous solution of sodium carbonate and then with water. The extracted organic layer was dried over Na2SO4, filtered, and concentrated under reduced pressure. To the obtained residue was added diisopropyl ether, and the precipitate was filtered and dried to afford tert-butyl(7-hydroxy-1-naphthyl)-carbamate (64.2 g, 79% yield).
- Next, to a mixture of tert-butyl (7-hydroxy-1-naphthyl)carbamate (64.0 g, 247 mmol) and cesium carbonate (161 g, 493 mmol) in 300 mL anhydrous DMF was added iodoethane (42.3 g, 272 mmol) at room temperature. The mixture was stirred at 60° C. for 2 hours. Water was added to the mixture, and the product was extracted with ethylacetate. The organic layer was washed with water and brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. To the obtained residue was added diisopropyl ether and the precipitate was collected and dried to afford tert-butyl (7-ethoxy-1-naphthyl)carbamate (47.9 g, 67.5% yield).
- Next, to a solution of tert-butyl (7-ethoxy-1-naphthyl)carbamate (47.9 g, 167 mmol) in 100 mL anhydrous. 1,4-dioxane was added 4N HCl in 1,4-dioxane (100 mL) at 0° C. The mixture was stirred at room temperature for 2 hours. Diisopropyl ether was added to the reaction mixture and the precipitate was filtered. To the obtained solid was added saturated sodium bicarbonate and the product was extracted with ethylacetate. The organic layer was dried over Na2SO4, filtered, and concentrated under reduced pressure to afford (7-ethoxy-1-naphthyl)amine (27.0 g, 86.3% yield).
- Next, to a flask containing a mixture of (7-ethoxy-1-naphthyl)amine (1.80 g, 9.61 mmol) and t-buthanol (2.13 g, 28.8 mmol) in tetrahydrofuran (20 mL) was collected liquid ammonia (300 mL) at −78° C. To the mixture was added lithium (0.200 g, 28.8 mmol) over 30 minutes and stirred at −78° C. for 1 hour. Methanol and water was added, and the mixture was stirred at room temperature for 16 hours to allow ammonia to evaporate. To the obtained residue was added ethylacetate. The organic layer was washed with water, dried over Na2SO4, filtered, and concentrated under reduced pressure to afford (7-ethoxy-5,8-dihydronaphthalen-1-yl)amine (1.37 g, 76% yield).
-
- To a stirred solution of (7-ethoxy-5,8-dihydronaphthalen-1-yl)amine (1.07 g, 5.65 mmol) in tetrahydrofuran (30 mL) was added solution of aqueous 2N HCl (10 mL), and stirred at 40° C. for 1 hour. The mixture was neutralized with addition of sodium bicorbonate, and the product was extracted with ethylacetate. The organic layer was washed with water, dried over Na2SO4, filtered, and concentrated under reduced pressure to afford 8-amino-3,4-dihydronaphthalen-2(1H)-one (0.71 g, 78% yield).
- Next, to 8-amino-3,4-dihydronaphthalen-2(1H)-one (0.050 g, 0.318 mmol) in methanol (10 mL) was added sodium borohydride (0.030 g, 0.175 mmol) at 0° C., and the mixture was stirred for 1 hour. The mixture was poured into water, and the product was extracted with ethylacetate. The organic layer was dried over Na2SO4, filtered, and concentrated under reduced pressure to afford 8-amino-1,2,3,4-tetrahydronaphthalen-2-ol (0.037 g, 71% yield).
-
- To a stirred solution of benzeneruthenium(II) chloride dimer (3.10 mg, 0.006 mmol) and (1S,2R)-(−)-cis-1-amino-2-indanol (3.7 mg, 0.025 mmol) in degaussed isopropanol was heated at 80° C. for 20 minutes under argon. The mixture was added to the solution of 8-amino-3,4-dihydronaphthalen-2(1H)-one (50 mg, 0.310 mmol) in isopropanol (3 mL) at room temperature. A solution of potassium hydroxide (3.48 mg, 0.062 mmol) in isopropanol (1 mL) was added, and the mixture was stirred at 45° C. for 1 hour. The mixture was passed through silica gel and washed with ethylacetate. The filtrate was concentrated under reduced pressure to afford the 8-amino-1,2,3,4-tetrahydro-naphthalen-2-ol chiral enantiomer (33.0 mg, 65% yield).
-
- To a solution of 3-fluoro-4-(trifluoromethyl)benzonitrile (300 mg, 1.59 mmol) in DMSO (5.0 mL) was added piperidine (675 mg, 7.93 mmol), and the mixture was stirred for 43 hours at 55° C. After the mixture was cooled to room temperature, ethylacetate was added and washed with water then brine. The organic layer was dried over MgSO4, filtered, and concentrated under reduced pressure. The obtained residue was purified by column chromatography on silica gel (hexane:ethylacetate 10:1) to afford 3-piperidin-1-yl-4-(trifluoromethyl)benzonitrile (353 mg, 88% yield).
- Next, to a suspension of lithium aluminum hydride (44.8 mg, 1.18 mmol) in tetrahydrofuran (5.0 mL) was added 3-piperidin-1-yl-4-(trifluoromethyl)benzonitrile (100.0 mg, 0.39 mmol) at 0° C. The mixture was stirred at 0° C. for 1 hour and at room temperature for 14 hours. To the mixture was added water and extracted with ethylacetate. The organic layer was dried over MgSO4, filtered, and concentrated under reduced pressure. The obtained residue was purified by column chromatography on silica gel (methanol:ethylacetate=1:2) to afford [3-piperidin-1-yl-4-(trifluoromethyl)benzyl]amine (46.8 mg, 46% yield).
-
- To a stirred solution of 8-amino-1,2,3,4-tetrahydro-naphthalen-2-ol (30.0 mg, 0.18 mmol) and pyridine (21.8 mg, 0.28 mmol) in 1.0 mL THE was added phenyl chloroformate (30.2 mg, 0.19 mmol), and the mixture was stirred for 1 hour at room temperature. To the product mixture was added water and extracted with ethylacetate. The organic layer was washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The obtained residue was triturated with ethylacetate and hexane to afford phenyl (7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)carbamate (25.2 mg, 48% yield).
-
- To a solution of (7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)carbamate (41.1 mg, 0.15 mmol) in DMSO (1.0 mL) was added [3-piperidin-1-yl-4-(trifluoromethyl)-benzyl]amine (45.0 mg, 0.17 mmol) at room temperature. The mixture was stirred for 1 hour and extracted with ethylacetate. The organic layer was washed with water then brine, dried over MgSO4, filtered, and concentrated under reduced pressure. The resulting solid was washed with diethylether to obtain N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N-[3-piperidin-1-yl-4-(trifluoromethyl)benzyl]urea (44.6 mg, 69% yield).
- 1H NMR (300 MHz, acetone): δ 1.56-1.70 (7H, m), 1.96 (1H, m), 2.49 (1H, dd), 2.75 (1H, m), 2.84-2.96 (6H, m), 4.05 (1H, m), 4.46 (2H, d), 6.67 (1H, brt), 6.79 (1H, d), 7.03 (1H, t), 7.26 (1H, d), 7.33 (1H, s), 7.48 (1H, s), 7.59 (1H, d), 7.67 (1H, d).
- mp 162.9° C.;
- Molecular weight: 447.50
- MS (M+H): 448
- Activity Class: A
- In the similar manner as described in Example 1-1, compounds in Example 1-2 to 1-28 as shown in Table 1 were synthesized.
-
TABLE 1 Ex- MS mp Activity No. STRUCTURE MW (M + H) (° C.) Class 1-2 365.48 366 >145Z A 1-3 367.45 368 >200Z C 1-4 401.90 402 >113Z A 1-5 379.51 380 147.9 A 1-6 381.48 382 239.3- 243.2 A 1-7 365.48 366 194.7- 196.7 A 1-8 433.48 434 180.5 A 1-9 433.48 434 170.2 A 1-10 461.53 462 144.8 A 1-11 461.53 462 92 A 1-12 450.51 451 90 A 1-13 437.54 438 70 C 1-14 423.56 424 119 A 1-15 458.40 459 150- 152 A 1-16 433.48 434 196.6 A 1-17 433.48 434 160.6 A 1-18 470.62 471 112- 114 A 1-19 447.50 448 153.4 A 1-20 519.57 520 63 A 1-21 491.51 492 163 C 1-22 477.53 478 153 A 1-23 463.50 464 81 A 1-24 490.53 491 87 C 1-25 448.49 449 125 D 1-26 449.48 450 71 A 1-27 437.5 438 amorphous A 1-28 449.5 450 amorphous A
Claims (21)
1-21. (canceled)
22. A method of treating a urological disorder or disease in a subject comprising administering to the subject an effective amount of a compound of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof:
wherein
n represents an integer of 0 to 6;
R1 represents hydrogen or C1-6 alkyl;
R2 and R3 together with the nitrogen atom to which they are attached, form a 3-8 membered saturated heterocyclic ring optionally interrupted by one or two atoms selected from the group consisting of oxygen, sulfur and nitrogen,
wherein said saturated heterocyclic ring has one or more substituents selected from the group consisting of halogen, benzyl, hydroxy, carboxy, amino, oxo, aminocarbonyl, C1-6 alkoxycarbonyl, and C1-6 alkyl optionally substituted by hydroxy, carboxy, C1-6 alkoxy, or C1-6 alkoxycarbonyl, or
R2 represents C2-6 alkenyl, C2-6 alkynyl, or C1-6 alkyl substituted by amino, hydroxy, C1-6 alkylamino, or di(C1-6 alkyl)amino;
R3 represents hydrogen, C2-6 alkenyl, C2-6 alkynyl, or C1-6 alkyl optionally substituted by amino, hydroxy, C1-6 alkylamino, or di(C1-6 alkyl)amino; and
R4 represents hydrogen, halogen, C1-6 alkylthio, C1-6 alkyl optionally substituted by mono-, di-, or tri-halogen, or C1-6 alkoxy optionally substituted by mono-, di-, or tri-halogen.
23. The method of claim 22 , wherein the urological disorder or disease is selected from the group consisting of urinary incontinence, urge urinary incontinence and overactive bladder.
24. The method of claim 22 , wherein R2 and R3 together with the nitrogen atom to which they are attached, form a 5-7 membered saturated heterocyclic ring optionally interrupted by one or two atoms selected from the group consisting of oxygen and nitrogen.
25. The method of claim 22 , wherein the compound is selected from the group consisting of:
N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N′-[3-piperidin-1-yl-4-(trifluoromethyl)benzyl]urea;
N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N′-[4-pyrrolidin-1-yl-3-(trifluoromethyl)benzyl]urea;
N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N′-[3-pyrrolidin-1-yl-4-(-trifluoromethyl)benzyl]urea;
N-[4-azepan-1-yl-3-(trifluoromethyl)benzyl]-N′-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;
N-[3-azepan-1-yl-4-(trifluoromethyl)benzyl]-N′-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;
N-(3-bromo-4-piperidin-1-ylbenzyl)-N′-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;
N-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-N′-[3-pyrrolidin-1-yl-4-(trifluoromethyl)benzyl]urea;
N-[(7S)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-N′-[3-pyrrolidin-1-yl-4-(trifluoromethyl)benzyl]urea;
N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N′-[4-piperidin-1-yl-3-(trifluoromethyl)benzyl]urea;
ethyl 1-[5-[({[(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)amino]carbonyl}amino)-methyl]-2-(trifluoromethyl)phenyl]piperidine-4-carboxylate;
N-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-N′-[3-morpholin-4-yl-4-(trifluoromethyl)benzyl]urea;
a tautomeric or stereoisomeric form of any of the foregoing compounds; and
a salt of any of the foregoing compounds.
26. The method of claim 22 , wherein the compound is N-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-N′-[3-pyrrolidin-1-yl-4-(trifluoromethyl)benzyl]urea, in its tautomeric or stereoisomeric form, or a salt thereof.
27. The method of claim 22 , wherein the compound is N-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-N′-[3-morpholin-4-yl-4-(trifluoromethyl)benzyl]urea, in its tautomeric or stereoisomeric form, or a salt thereof.
28. A method of treating pain in a subject comprising administering to the subject an effective amount of a compound of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof:
wherein
n represents an integer of 0 to 6;
R1 represents hydrogen or C1-6 alkyl;
R2 and R3 together with the nitrogen atom to which they are attached, form a 3-8 membered saturated heterocyclic ring optionally interrupted by one or two atoms selected from the group consisting of oxygen, sulfur and nitrogen,
wherein said saturated heterocyclic ring has one or more substituents selected from the group consisting of halogen, benzyl, hydroxy, carboxy, amino, oxo, aminocarbonyl, C1-6 alkoxycarbonyl, and C1-6 alkyl optionally substituted by hydroxy, carboxy, C1-6 alkoxy, or C1-6 alkoxycarbonyl, or
R2 represents C2-6 alkenyl, C2-6 alkynyl, or C1-6 alkyl substituted by amino, hydroxy, C1-6 alkylamino, or di(C1-6 alkyl)amino;
R3 represents hydrogen, C2-6 alkenyl, C2-6 alkynyl, or C1-6 alkyl optionally substituted by amino, hydroxy, C1-6 alkylamino, or di(C1-6 alkyl)amino; and
R4 represents hydrogen, halogen, C1-6 alkylthio, C1-6 alkyl optionally substituted by mono-, di-, or tri-halogen, or C1-6 alkoxy optionally substituted by mono-, di-, or tri-halogen.
29. The method of claim 28 , wherein the pain is selected from the group consisting of chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, musculoskeletal pain, back pain, orofascial pain, headache, visceral pain, pelvic pain, vulvodynia, orchialgia and prostatodynia.
30. The method of claim 28 , wherein the pain is pain associated with a disease or disorder.
31. The method of claim 30 , wherein the disease or disorder is selected from the group consisting of neuralgia, a neuropathy, algesia, nerve injury, ischaemia, neurodegeneration, stroke, arthritis, cancer, irritable bowel syndrome and inflammatory lesions of joints, skin, muscles and nerves.
32. The method of claim 28 , wherein R2 and R3 together with the nitrogen atom to which they are attached, form a 5-7 membered saturated heterocyclic ring optionally interrupted by one or two atoms selected from the group consisting of oxygen and nitrogen.
33. The method of claim 28 , wherein the compound is selected from the group consisting of:
N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N′-[3-piperidin-1-yl-4-(trifluoromethyl)benzyl]urea;
N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N′-[4-pyrrolidin-1-yl-3-(trifluoromethyl)benzyl]urea;
N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N′-[3-pyrrolidin-1-yl-4-(-trifluoromethyl)benzyl]urea;
N-[4-azepan-1-yl-3-(trifluoromethyl)benzyl]-N′-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;
N-[3-azepan-1-yl-4-(trifluoromethyl)benzyl]-N′-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;
N-(3-bromo-4-piperidin-1-ylbenzyl)-N′-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;
N-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-N′-[3-pyrrolidin-1-yl-4-(trifluoromethyl)benzyl]urea;
N-[(7S)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-N′-[3-pyrrolidin-1-yl-4-(trifluoromethyl)benzyl]urea;
N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N′-[4-piperidin-1-yl-3-(trifluoromethyl)benzyl]urea;
ethyl 1-[5-[({[(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)amino]carbonyl}amino)-methyl]-2-(trifluoromethyl)phenyl]piperidine-4-carboxylate;
N-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-N′-[3-morpholin-4-yl-4-(trifluoromethyl)benzyl]urea;
a tautomeric or stereoisomeric form of any of the foregoing compounds; and
a salt of any of the foregoing compounds.
34. The method of claim 28 , wherein the compound is N-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-N′-[3-pyrrolidin-1-yl-4-(trifluoromethyl)benzyl]urea, in its tautomeric or stereoisomeric form, or a salt thereof.
35. The method of claim 28 , wherein the compound is N-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-N′-[3-morpholin-4-yl-4-(trifluoromethyl)benzyl]urea, in its tautomeric or stereoisomeric form, or a salt thereof.
36. A method of treating an inflammatory disorder or disease in a subject comprising administering to the subject an effective amount of a compound of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof:
wherein
n represents an integer of 0 to 6;
R1 represents hydrogen or C1-6 alkyl;
R2 and R3 together with the nitrogen atom to which they are attached, form a 3-8 membered saturated heterocyclic ring optionally interrupted by one or two atoms selected from the group consisting of oxygen, sulfur and nitrogen,
wherein said saturated heterocyclic ring has one or more substituents selected from the group consisting of halogen, benzyl, hydroxy, carboxy, amino, oxo, aminocarbonyl, C1-6 alkoxycarbonyl, and C1-6 alkyl optionally substituted by hydroxy, carboxy, C1-6 alkoxy, or C1-6 alkoxycarbonyl, or
R2 represents C2-6 alkenyl, C2-6 alkynyl, or C1-6 alkyl substituted by amino, hydroxy, C1-6 alkylamino, or di(C1-6 alkyl)amino;
R3 represents hydrogen, C2-6 alkenyl, C2-6 alkynyl, or C1-6 alkyl optionally substituted by amino, hydroxy, C1-6 alkylamino, or di(C1-6 alkyl)amino; and
R4 represents hydrogen, halogen, C1-6 alkylthio, C1-6 alkyl optionally substituted by mono-, di-, or tri-halogen, or C1-6 alkoxy optionally substituted by mono-, di-, or tri-halogen.
37. The method of claim 36 , wherein the inflammatory disorder or disease is selected from the group consisting of asthma and COPD.
38. The method of claim 36 , wherein R2 and R3 together with the nitrogen atom to which they are attached, form a 5-7 membered saturated heterocyclic ring optionally interrupted by one or two atoms selected from the group consisting of oxygen and nitrogen.
39. The method of claim 36 , wherein the compound is selected from the group consisting of:
N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N′-[3-piperidin-1-yl-4-(trifluoromethyl)benzyl]urea;
N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N′-[4-pyrrolidin-1-yl-3-(trifluoromethyl)benzyl]urea;
N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N′-[3-pyrrolidin-1-yl-4-(-trifluoromethyl)benzyl]urea;
N-[4-azepan-1-yl-3-(trifluoromethyl)benzyl]-N′-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;
N-[3-azepan-1-yl-4-(trifluoromethyl)benzyl]-N′-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;
N-(3-bromo-4-piperidin-1-ylbenzyl)-N′-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)urea;
N-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-N′-[3-pyrrolidin-1-yl-4-(trifluoromethyl)benzyl]urea;
N-[(7S)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-N′-[3-pyrrolidin-1-yl-4-(trifluoromethyl)benzyl]urea;
N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)-N′-[4-piperidin-1-yl-3-(trifluoromethyl)benzyl]urea;
ethyl 1-[5-[({[(7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)amino]carbonyl}amino)-methyl]-2-(trifluoromethyl)phenyl]piperidine-4-carboxylate;
N-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-N′-[3-morpholin-4-yl-4-(trifluoromethyl)benzyl]urea;
a tautomeric or stereoisomeric form of any of the foregoing compounds; and
a salt of any of the foregoing compounds.
40. The method of claim 36 , wherein the compound, its tautomeric or stereoisomeric form, or a salt thereof is N-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-N′-[3-pyrrolidin-1-yl-4-(trifluoromethyl)benzyl]urea.
41. The method of claim 36 , wherein the compound is N-[(7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]-N′-[3-morpholin-4-yl-4-(trifluoromethyl)benzyl]urea, in its tautomeric or stereoisomeric form, or a salt thereof.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/432,600 US20090209514A1 (en) | 2002-12-09 | 2009-04-29 | Tetrahydro-Naphthalene Derivatives as Vanilloid Receptor Antagonists |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02027528 | 2002-12-09 | ||
EP02027528.5 | 2002-12-09 | ||
PCT/EP2003/013452 WO2004052845A1 (en) | 2002-12-09 | 2003-11-28 | Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists |
US10/537,217 US7544716B2 (en) | 2002-12-09 | 2003-11-28 | Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists |
US12/432,600 US20090209514A1 (en) | 2002-12-09 | 2009-04-29 | Tetrahydro-Naphthalene Derivatives as Vanilloid Receptor Antagonists |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/013452 Continuation WO2004052845A1 (en) | 2002-12-09 | 2003-11-28 | Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists |
US10/537,217 Continuation US7544716B2 (en) | 2002-12-09 | 2003-11-28 | Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090209514A1 true US20090209514A1 (en) | 2009-08-20 |
Family
ID=32479714
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/537,217 Expired - Fee Related US7544716B2 (en) | 2002-12-09 | 2003-11-28 | Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists |
US12/432,600 Abandoned US20090209514A1 (en) | 2002-12-09 | 2009-04-29 | Tetrahydro-Naphthalene Derivatives as Vanilloid Receptor Antagonists |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/537,217 Expired - Fee Related US7544716B2 (en) | 2002-12-09 | 2003-11-28 | Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists |
Country Status (11)
Country | Link |
---|---|
US (2) | US7544716B2 (en) |
EP (1) | EP1572632B1 (en) |
JP (1) | JP4440113B2 (en) |
AT (1) | ATE404531T1 (en) |
AU (1) | AU2003288200A1 (en) |
CA (1) | CA2508845C (en) |
DE (1) | DE60322946D1 (en) |
DK (1) | DK1572632T3 (en) |
ES (1) | ES2311744T3 (en) |
PT (1) | PT1572632E (en) |
WO (1) | WO2004052845A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8173841B2 (en) | 2002-12-06 | 2012-05-08 | Xention Limited | Tetrahydro-naphthalene derivatives |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003097806A2 (en) * | 2002-05-16 | 2003-11-27 | Cytovia, Inc. | Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof |
JP4440113B2 (en) * | 2002-12-09 | 2010-03-24 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists |
EP1616862A4 (en) * | 2003-04-18 | 2008-07-16 | Ono Pharmaceutical Co | Nitrogenous heterocyclic compound and use thereof |
WO2005040119A1 (en) * | 2003-10-01 | 2005-05-06 | Bayer Healthcare Ag | Tetrahydro-naphthalene and urea derivatives |
EP1679296A4 (en) | 2003-10-14 | 2007-12-26 | Ajinomoto Kk | Ether derivative |
CA2542494A1 (en) * | 2003-10-15 | 2005-05-06 | Bayer Healthcare Ag | Tetrahydro-naphthalene and urea derivatives |
WO2005044802A2 (en) | 2003-11-08 | 2005-05-19 | Bayer Healthcare Ag | Tetrahydro-quinolinylurea derivatives as vrl antagonists |
JP2008532956A (en) * | 2005-03-05 | 2008-08-21 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | Use of hydroxytetrahydro-naphthalene derivatives |
DE102005023944A1 (en) | 2005-05-20 | 2006-11-23 | Grünenthal GmbH | Substituted benzo-fused cycloheptanone derivatives and their use for the preparation of medicaments |
MX2009003469A (en) * | 2006-10-04 | 2009-05-28 | Neurokey As | Use of hypothermia inducing drugs to treat ischemia. |
EP2134678A2 (en) | 2006-12-20 | 2009-12-23 | Abbott Laboratories | N-(5, 6, 7, 8-tetrahydronaphthalen-1-yl) urea derivatives and related compounds as trpv1 vanilloid receptor antagonists for the treatment of pain |
DE102022104759A1 (en) | 2022-02-28 | 2023-08-31 | SCi Kontor GmbH | Co-crystal screening method, in particular for the production of co-crystals |
Citations (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2004763A (en) * | 1932-06-11 | 1935-06-11 | Du Pont | N (p-amino-phenyl) morpholine and method of preparing the same |
US3142699A (en) * | 1958-04-24 | 1964-07-28 | Bayer Ag | Urethane compounds and process therefor |
US3239480A (en) * | 1962-02-03 | 1966-03-08 | Bayer Ag | Polyurethanes synthesized with the aid of carboxylic acid salts |
US3878206A (en) * | 1973-06-06 | 1975-04-15 | Morton Norwich Products Inc | 9-(Substituted amino)imidazo{8 4,5-f{9 quinolines |
US4443473A (en) * | 1981-06-30 | 1984-04-17 | The Procter & Gamble Company | Carbamate derivatives |
US4477389A (en) * | 1982-10-25 | 1984-10-16 | The United States Of America As Represented By The Secretary Of Agriculture | Polyhalogenated phenyl isocyanate synthesis with excess phosgene and either triethylamine or tetramethylurea |
US5453426A (en) * | 1989-04-19 | 1995-09-26 | The United States Of America As Represented By The Department Of Health And Human Services | Sulfur-containing xanthine derivatives as adenosine antagonists |
US6333337B1 (en) * | 1998-01-27 | 2001-12-25 | Icagen, Inc. | Potassium channel inhibitors |
US6683107B2 (en) * | 1998-05-12 | 2004-01-27 | Wyeth | Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia |
US20040082661A1 (en) * | 2001-03-09 | 2004-04-29 | Rami Harshad Kantilal | Urea derivatives having vanilloid receptor (vr1) antagonist activity |
US6743814B2 (en) * | 2000-03-09 | 2004-06-01 | Nihon Bayer Agrochem K.K. | Nematicidal trifluorobutenes |
US20040259875A1 (en) * | 2001-07-31 | 2004-12-23 | Takeshi Yura | Amine derivatives |
US6841519B1 (en) * | 1999-08-10 | 2005-01-11 | Kumiai Chemical Industry Co., Ltd. | Isoxazoline derivatives and herbicides containing the same as the active ingredient |
US20050165049A1 (en) * | 2004-01-23 | 2005-07-28 | Christopher Hulme | Vanilloid receptor ligands and their use in treatments |
US20050165046A1 (en) * | 2004-01-23 | 2005-07-28 | Christopher Hulme | Vanilloid receptor ligands and their use in treatments |
US20060058342A1 (en) * | 2002-11-18 | 2006-03-16 | Fariborz Firoodznia | Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases |
US7015233B2 (en) * | 2003-06-12 | 2006-03-21 | Abbott Laboratories | Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor |
US7045533B2 (en) * | 2000-11-24 | 2006-05-16 | Novartis Ag | Naphthalene derivatives |
US20060142333A1 (en) * | 2002-02-15 | 2006-06-29 | Macdonald Gregor J | Vanilloid receptor modulators |
US20060258742A1 (en) * | 2002-05-08 | 2006-11-16 | Bayer Heaithcare Ag | Hydroxy tetrahydro-naphthalenylurea derivatives |
US7381840B2 (en) * | 2002-12-06 | 2008-06-03 | Xention Limited | Tetrahydro-naphthalene derivatives |
US7544716B2 (en) * | 2002-12-09 | 2009-06-09 | Xention Limited | Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists |
US7615557B2 (en) * | 2003-10-01 | 2009-11-10 | Xention Limited | Tetrahydro-naphthalene and urea derivatives |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000050387A1 (en) * | 1999-02-22 | 2000-08-31 | Pacific Corporation | Vanilloid analogues containing resiniferatoxin pharmacophores as potent vanilloid receptor agonists and analgesics, compositions and uses thereof |
EP1163236B1 (en) * | 1999-03-12 | 2005-11-09 | Boehringer Ingelheim Pharmaceuticals Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
US6294694B1 (en) * | 1999-06-04 | 2001-09-25 | Wisconsin Alumni Research Foundation | Matrix metalloproteinase inhibitors and method of using same |
CL2003001415A1 (en) * | 2002-07-12 | 2005-01-07 | Janssen Pharmaceutica Nv | COMPOUNDS D DERIVED FROM NAFTIL, QUINOLINIL AND ISOQUINOLINIL UREA; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT AND PREVENTION OF PAIN CONDITIONS AND IN THE SYRNDROME OF THE IRRITABLE COLON AND ASSOCIATED CONDITIONS. |
US7375126B2 (en) * | 2003-06-12 | 2008-05-20 | Abbott Laboratories | Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
-
2003
- 2003-11-28 JP JP2004557950A patent/JP4440113B2/en not_active Expired - Fee Related
- 2003-11-28 DE DE60322946T patent/DE60322946D1/en not_active Expired - Lifetime
- 2003-11-28 AU AU2003288200A patent/AU2003288200A1/en not_active Abandoned
- 2003-11-28 ES ES03780088T patent/ES2311744T3/en not_active Expired - Lifetime
- 2003-11-28 WO PCT/EP2003/013452 patent/WO2004052845A1/en active IP Right Grant
- 2003-11-28 AT AT03780088T patent/ATE404531T1/en active
- 2003-11-28 PT PT03780088T patent/PT1572632E/en unknown
- 2003-11-28 CA CA2508845A patent/CA2508845C/en not_active Expired - Fee Related
- 2003-11-28 DK DK03780088T patent/DK1572632T3/en active
- 2003-11-28 US US10/537,217 patent/US7544716B2/en not_active Expired - Fee Related
- 2003-11-28 EP EP03780088A patent/EP1572632B1/en not_active Expired - Lifetime
-
2009
- 2009-04-29 US US12/432,600 patent/US20090209514A1/en not_active Abandoned
Patent Citations (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2004763A (en) * | 1932-06-11 | 1935-06-11 | Du Pont | N (p-amino-phenyl) morpholine and method of preparing the same |
US3142699A (en) * | 1958-04-24 | 1964-07-28 | Bayer Ag | Urethane compounds and process therefor |
US3239480A (en) * | 1962-02-03 | 1966-03-08 | Bayer Ag | Polyurethanes synthesized with the aid of carboxylic acid salts |
US3878206A (en) * | 1973-06-06 | 1975-04-15 | Morton Norwich Products Inc | 9-(Substituted amino)imidazo{8 4,5-f{9 quinolines |
US4443473A (en) * | 1981-06-30 | 1984-04-17 | The Procter & Gamble Company | Carbamate derivatives |
US4477389A (en) * | 1982-10-25 | 1984-10-16 | The United States Of America As Represented By The Secretary Of Agriculture | Polyhalogenated phenyl isocyanate synthesis with excess phosgene and either triethylamine or tetramethylurea |
US5453426A (en) * | 1989-04-19 | 1995-09-26 | The United States Of America As Represented By The Department Of Health And Human Services | Sulfur-containing xanthine derivatives as adenosine antagonists |
US6333337B1 (en) * | 1998-01-27 | 2001-12-25 | Icagen, Inc. | Potassium channel inhibitors |
US6683107B2 (en) * | 1998-05-12 | 2004-01-27 | Wyeth | Furans, benzofurans, and thiophenes useful in the treatment of insulin resistance and hyperglycemia |
US6841519B1 (en) * | 1999-08-10 | 2005-01-11 | Kumiai Chemical Industry Co., Ltd. | Isoxazoline derivatives and herbicides containing the same as the active ingredient |
US6743814B2 (en) * | 2000-03-09 | 2004-06-01 | Nihon Bayer Agrochem K.K. | Nematicidal trifluorobutenes |
US7045533B2 (en) * | 2000-11-24 | 2006-05-16 | Novartis Ag | Naphthalene derivatives |
US20040082661A1 (en) * | 2001-03-09 | 2004-04-29 | Rami Harshad Kantilal | Urea derivatives having vanilloid receptor (vr1) antagonist activity |
US20040259875A1 (en) * | 2001-07-31 | 2004-12-23 | Takeshi Yura | Amine derivatives |
US20060142333A1 (en) * | 2002-02-15 | 2006-06-29 | Macdonald Gregor J | Vanilloid receptor modulators |
US7612113B2 (en) * | 2002-05-08 | 2009-11-03 | Xention Limited | Hydroxy tetrahydro-naphthalenylurea derivatives |
US20060258742A1 (en) * | 2002-05-08 | 2006-11-16 | Bayer Heaithcare Ag | Hydroxy tetrahydro-naphthalenylurea derivatives |
US20060058342A1 (en) * | 2002-11-18 | 2006-03-16 | Fariborz Firoodznia | Imidazo[1,5-a]pyridine derivatives and methods for treating aldosterone mediated diseases |
US20080275047A1 (en) * | 2002-12-06 | 2008-11-06 | Masaomi Tajimi | Tetrahydro-naphthalene derivatives |
US7381840B2 (en) * | 2002-12-06 | 2008-06-03 | Xention Limited | Tetrahydro-naphthalene derivatives |
US7544716B2 (en) * | 2002-12-09 | 2009-06-09 | Xention Limited | Tetrahydro-naphthalene derivatives as vanilloid receptor antagonists |
US7015233B2 (en) * | 2003-06-12 | 2006-03-21 | Abbott Laboratories | Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor |
US7615557B2 (en) * | 2003-10-01 | 2009-11-10 | Xention Limited | Tetrahydro-naphthalene and urea derivatives |
US20050165046A1 (en) * | 2004-01-23 | 2005-07-28 | Christopher Hulme | Vanilloid receptor ligands and their use in treatments |
US20050165049A1 (en) * | 2004-01-23 | 2005-07-28 | Christopher Hulme | Vanilloid receptor ligands and their use in treatments |
Non-Patent Citations (1)
Title |
---|
"Provesica Publishes XEN-D0501 Phase 1 Data on Innovative new Medicine for Overactive Bladder" Online: "http://www.drugs.com/clinical_trials/provesica-publishes-xen-d0501-phase-1-data-innovative-new-medicine-overactive-bladder-12719.html" accessed August 1, 2013. * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8173841B2 (en) | 2002-12-06 | 2012-05-08 | Xention Limited | Tetrahydro-naphthalene derivatives |
Also Published As
Publication number | Publication date |
---|---|
CA2508845A1 (en) | 2004-06-24 |
EP1572632A1 (en) | 2005-09-14 |
WO2004052845A8 (en) | 2005-06-09 |
AU2003288200A1 (en) | 2004-06-30 |
CA2508845C (en) | 2012-02-21 |
US7544716B2 (en) | 2009-06-09 |
JP4440113B2 (en) | 2010-03-24 |
ATE404531T1 (en) | 2008-08-15 |
WO2004052845A1 (en) | 2004-06-24 |
US20060135505A1 (en) | 2006-06-22 |
PT1572632E (en) | 2008-09-19 |
AU2003288200A8 (en) | 2004-06-30 |
DE60322946D1 (en) | 2008-09-25 |
JP2006509017A (en) | 2006-03-16 |
EP1572632B1 (en) | 2008-08-13 |
ES2311744T3 (en) | 2009-02-16 |
DK1572632T3 (en) | 2008-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8088826B2 (en) | Tetrahydro-naphthalene derivatives | |
US20090209514A1 (en) | Tetrahydro-Naphthalene Derivatives as Vanilloid Receptor Antagonists | |
US7615557B2 (en) | Tetrahydro-naphthalene and urea derivatives | |
US20080045546A1 (en) | Tetradydro-Naphthalene And Urea Derivatives | |
US20100137361A1 (en) | Tetrahydro-Quinolinylurea Derivatives | |
US7612113B2 (en) | Hydroxy tetrahydro-naphthalenylurea derivatives | |
EP1687262B1 (en) | Bicyclic amide, carbamate or urea derivatives as vanilloid receptor modulators | |
US7423175B2 (en) | Hydroxy-tetrahydro-naphthalenylurea derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |